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Prostate cancer is the most common non-cutaneous cancer and the second leading 
cause of cancer death among US men. Findings from previous studies suggest that 
metabolic conditions, including type 2 diabetes, hypertension and obesity may be 
associated with prostate cancer risk. As these conditions become increasingly prevalent, 
it is crucial to gain a better understanding how these conditions influence the risk of 
prostate cancer over time and how they influence prostate cancer detection. Therefore, 
the goal of this dissertation was to estimate the effects of type 2 diabetes, hypertension, 
and obesity on prostate-cancer risk and detection over 15 years of follow-up, utilizing the 
resources of The Olmsted County Study of Urinary Symptoms and Health Status among 
Men (OCS). In 1990, a randomly selected cohort of Caucasian men ages 40-79 was 
recruited; 2,445 completed a questionnaire that included physician-diagnosed diabetes 
and hypertension. Anthropometric measures were collected during clinical examination. 
Biopsy-confirmed prostate cancer was identified from medical records. A 25% random 
subset was invited to participate in a urologic exam, during which serum prostate specific 
antigen levels were measured. Proportional hazards (Cox) regression was used to 
estimate the effects of these metabolic conditions, both individually and in combination, 
on the incidence rate of prostate cancer and likelihood of prostate cancer biopsy. Mixed 
effects linear regression was used to estimate the effects of these metabolic conditions on 
changes in prostate specific antigen levels and prostate volume. Type 2 diabetes, obesity 
 xii 
and hypertension, alone and in combinations with each other were differentially 
associated with prostate cancer risk. Men with diabetes experienced greater age-adjusted 
reductions in PSA levels than did non-diabetic men. Baseline body mass index was 
inversely associated with the annual percent change in PSA and positively associated 
with the annual percent change in prostate volume. These results suggest that the 
presence of these metabolic conditions influences both the risk and detection of prostate 
cancer. Findings from these studies will set the direction for the next set of investigations 
to elucidate these associations and provide clues to understanding the etiology, as well as 











Prostate cancer is the most common non-cutaneous cancer among American men and 
is the second leading cause of cancer death in the United States (1, 2). The incidence of 
this disease is estimated to have exceeded 192,280 cases and 27,360 deaths in 2009 alone 
(2). Extensive literature has been published investigating various factors that may 
influence prostate cancer risk, currently focusing on the role of the metabolic syndrome 
and its components, specifically, type 2 diabetes mellitus (T2DM) and obesity.  Type 2 
diabetes, hypertension and obesity are all highly prevalent conditions in the elderly US 
population with an estimated 68% of US adults described as overweight and/or obese 
(3),1 in 3 US adults are hypertensive, and 11% of US men diagnosed with diabetes (4). 
Metabolic syndrome is also becoming increasingly prevalent, affecting approximately a 
quarter of US adults (5). These conditions have arguably reached epidemic proportions 
and are thought, in part, to explain the increase in chronic disease seen in this country (6). 
Although previous literature has implicated these metabolic disturbances in prostate 
cancer development, the literature in this field is both inconsistent and methodologically 
limited. To date, the majority of findings suggest that obesity is inversely associated with 
the incidence of prostate cancer, and this association may differ by stage of disease at 
diagnosis. Although the relation of T2DM with prostate cancer remains somewhat 
unclear, the metabolic syndrome has been found to be positively associated with the risk 
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of prostate cancer. Not only are the interpretations of these results controversial, but the 
impact of the increasing prevalence of these conditions on prostate specific antigen (PSA) 
levels is only beginning to be investigated. This is particularly relevant as Freedland et al. 
(7) suggested that PSA testing, currently our most utilized prostate cancer screening tool, 
is less predictive in obese men. This has been attributed to overweight men having 
decreased PSA levels (8, 9) and to increased prostate volumes, which make cancer 
detection by biopsy and digital rectal examination more difficult. Furthermore, lower 
PSA levels in obese men with prostate cancer have been attributed to plasma 
hemodilution (10). Others have argued that the inverse association between obesity and 
prostate cancer is due to detection bias, resulting from the association of obesity with 
PSA level or prostate volume among men at risk of prostate cancer (7, 11). Other 
explanations for the inverse association seen between obesity and prostate cancer include 
the use of varying measures of obesity, heterogeneity of study populations, heterogeneity 
across disease stage at diagnosis, as well as hormone levels. 
Similar conflicting observations have been reported for T2DM with time since 
diagnoses having varying associations with prostate cancer risk. These inconsistent 
findings have been attributed to changes in insulin concentration during the course of 
diabetes development and progression. Given the gap in our clear understanding of these 
relations, investigating the possible effects of metabolic disturbances on both prostate 
cancer risk and detection in a prospective, longitudinal study that allows for the careful 
consideration of potential confounders and effect modifiers is crucial for our 
understanding of these complex associations.  Thus, the focus of this dissertation was to 
investigate the role of the metabolic syndrome and its components in prostate cancer 
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development and determine how these factors impact prostate cancer detection in a 
population-based sample of men aged 40-79.  
I utilized The Olmsted County Study of Urinary Symptoms and Health Status among 
Men (OCS) to complete this dissertation. This ongoing NIH-funded, longitudinal, 
population-based study of Caucasian men provides a unique opportunity in that it 
contains clinical data with extensive covariate measurements collected through 
comprehensive physical examinations and reliable, well-tested questionnaires over 15 
years of follow-up thus far. Findings from this dissertation will help to inform future 
studies as these metabolic conditions and prostate cancer continue to become increasingly 
prevalent. Determining the impact of metabolic disturbances on prostate cancer risk and 
detection may also help to shape better prevention strategies in the future for prostate 














Prostate cancer is the second most common non-cutaneous cancer and leading 
cause of cancer deaths in US men (1). While only 15% of men diagnosed with prostate 
cancer will die from it, the prevalence of clinically diagnosed disease remains high. 
Currently, prostate specific antigen (PSA) testing and digital rectal examination (DRE) 
are used in conjunction with prostate needle-biopsy to detect prostate cancer. PSA is the 
most common screening test for prostate cancer with 58% of Caucasian men receiving an 
annual test (12). Recently, the specificity of the test and impact on mortality has been 
questioned as most men who are subjected to biopsy after an abnormal PSA test are 
found not to have prostate cancer (13). The low specificity of PSA testing and 
questionable benefit of PSA screening on prostate cancer mortality highlight the need for 
better detection strategies for prostate cancer (14, 15). Knowledge of the influence of 
concomitant comorbidities on serum PSA concentrations may improve the discriminant 
value of this test and reduce the number of unnecessary biopsies and subsequent 
overdiagnosis of indolent cancers. 
 
Metabolic Syndrome  
Metabolic syndrome, defined as a cluster of metabolic disturbances, including 
diabetes, hypertension, abdominal obesity, lipid disorders and disturbances in glucose 
metabolism related to hyperinsulinemia and insulin resistance (IR), has become a world-
wide epidemic with significant consequences for the aging population. Not only has it 
been estimated that a quarter of US adults are suffering from metabolic syndrome (5, 16), 
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but metabolic syndrome has also been found to be positively associated with the risk of 
many common chronic diseases, including cardiovascular disease (ischemic heart disease 
and stroke), type 2 diabetes mellitus (T2DM), and multiple types of cancer (17). The 
clustering of these conditions is often referred to as a syndrome because it is thought that 
these conditions share an underlying pathophysiological component, insulin resistance 
(18). Currently, three definitions are used to describe this syndrome with two of the most 
widely used presented below (Table 1.1). The definitions of the World Health 
Organization (WHO), the National Cholesterol Education Program’s Adult Treatment 
Panel III (ATP III), and the European Group on Insulin Resistance  agree that 
dyslipidemia, glucose intolerance, obesity, insulin resistance and hypertension all 
contribute to the syndrome.  




Obesity is a growing global epidemic, with more than half of the world’s adults 
categorized as being overweight and up to 30% categorized as obese (body mass index 
[BMI] >30 kg/m2) (19). In the US alone, 68% of adults are either overweight or obese 
(3). Furthermore, obesity has been found to be associated with a number of medical 
conditions including hypertension, dyslipidemia, diabetes, hypertriglyceridemia (20), and 
more recently several types of cancer (17).  
 
Hypertension 
Hypertension, or high blood pressure, is one of the most prevalent chronic 
diseases in the United States, with one in three Americans afflicted (21). Not only is this 
condition prevalent, but it is also a very costly with an estimated 77 billion dollars 
expected to be spent on it in 2010 alone (22). Furthermore, hypertension is a risk factor 
for kidney disease, congestive heart failure, myocardial infarction, and stroke, which are 
the first and third most common causes of mortality in the United States (21). 
 
Type 2 Diabetes Mellitus 
Type 2 diabetes mellitus, a chronic disorder of carbohydrate, fat and protein 
metabolism, is a important cause of morbidity and mortality in the U.S (23). The Centers 
for Disease Control and Prevention (CDC) estimate that diabetes mellitus affects 18 
million American adults (6). Using data from the Behavioral Risk Factor Surveillance 
System, Mokdad et al. (24) found that the prevalence of diabetes increased from 4.9% in 
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1990 to 7.3% in the U.S. in 2000, representing an increase of 49%. This change is 
striking as it is estimated that 5.9 million Americans are still unaware that they have the 
disease, thus greatly increasing the potential prevalence in the community (23). Patients 
with diabetes have an increased incidence of atherosclerotic cardiovascular, peripheral 
arterial, and cerebrovascular disease. In addition, hypertension and abnormalities of 
lipoprotein metabolism are often found in people with diabetes. The morbidity associated 
with long-standing diabetes results from these complications. Although there is some 
literature suggesting that complications are a genetic concomitant unrelated to metabolic 
abnormalities, most of the available evidence suggests that the complications of diabetes 
mellitus are a consequence of the metabolic derangements associated with the disease 
(25). The role of circulating insulin concentration in the development of type 2 diabetes 
has been controversial with both insulin excess and insulin deficiency having been 
postulated as important antecedents.  Prospective epidemiologic studies of type 2 diabetes 
incidence in which insulin levels were measured suggest that the initial event leading to 
diabetes is peripheral resistance to insulin action, known as insulin resistance.  
 
Metabolic conditions and Prostate Cancer Overview 
Recent literature has suggested that features of the metabolic syndrome may be 
predictive of prostate cancer risk. The presence of multiple components of metabolic 
syndrome has been shown to increase the risk of prostate cancer development as well as 
play a role in disease progression. Specifically, in a prospective study of 16,209 men, 
those with more than three components of the metabolic syndrome were 1.5 times more 
likely to be diagnosed with prostate cancer in the 27 years of follow-up than were men 
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with no metabolic syndrome components (26). Hammarstan et al. (27) found that men 
with disseminated (T3) prostate cancer were more likely to have 3 components of the 
metabolic syndrome compared to men with localized (T2) disease. Furthermore, a 
prospective study of Finnish men found that men with the metabolic syndrome have a 2-
fold increased risk of developing prostate cancer and that the risk is greater in men with a 
BMI greater than 27 kg/m2 than in men with a BMI less than 27 kg/m2 (28). In addition 
to the overall cluster of conditions known as the metabolic syndrome being related to 
prostate cancer development, the main metabolic components of the syndrome, obesity 
and T2DM, have also been shown to be influence PSA levels (8, 29).  
 
Obesity and Prostate Cancer 
While large population-based studies have shown that BMI is associated with an 
increased risk of prostate cancer (30-33), other studies have found either no association or 
an inverse association between obesity and prostate cancer incidence (34-36). In a recent 
meta-analysis of 22 prospective studies, MacInnis and English (37) concluded that 
obesity was weakly associated with an increased risk of prostate cancer, and the 
association varied appreciably across studies (37). Possible explanations for conflicting 
results include variations in the measurements of obesity between studies and at different 
times in the life course, differences in study design, insufficient control of confounders, 
different distributions of effect modifiers and obesity in the study populations. Three 
recent large prospective cohort studies found that obesity was differentially associated 
with aggressive and non-aggressive forms of prostate cancers;  a reduced risk of low-
stage disease and an increased risk of high-stage disease was observed for obese men (38-
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40). It is not clear if these findings are the result of obesity affecting the type of prostate 
cancer, if obesity is a prognostic marker for prostate cancer progression, or if obesity 
simply affects the detection of prostate cancer. A biologically plausible explanation for 
this finding is that obese men have lower levels of testosterone that may prevent prostate 
cancer or delay detection (7, 41). Obesity is known to alter serum concentrations of 
hormones such as testosterone, estrogen, insulin, IGF-1, and leptin, all of which are 
associated with prostate cancer (7). Finally, an increase in the production of inflammatory 
markers, thought to underlie prostate cancer pathogenesis, has been recently observed to 
be associated with obesity. A conceptualized and plausible biological pathway through 





IGF-1: Insulin growth factor 1, IGFBP-1: Insulin growth factors binding protein 1, SHBG: Sex hormone 
binding globulin 
Figure 1-1: Conceptualized model of pathogenesis of prostate cancer and metabolic disturbances 
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Obesity and PSA 
In addition to its effect on prostate cancer pathogenesis, obesity may also influence 
the detection of prostate cancer through its impact on prostate-cancer screening, PSA 
level, difficulty in performing DREs (affecting their results), and prostate volume 
(affecting biopsy results). In fact, several recent studies have suggested that detection bias 
associated with obesity may partly explain the inverse association between obesity and 
prostate cancer incidence (7, 11, 42). Digital rectal examinations known to be more 
difficult to perform in obese men may lead to an increased number of missed diagnoses 
(11). Additionally, elevated PSA levels are considered a marker for prostate cancer 
presence; however, needle-biopsy is necessary for confirmation. Obese men have lower 
PSA levels than do non-obese men (8, 11, 41), and PSA decreases with increasing 
concomitant BMI levels (9, 43, 44). These inverse associations are possibly due to 
decreased testosterone concentrations and resulting PSA (7) or to lower PSA levels as a 
result of plasma hemodilution in obese men (10). As a result, it is possible that obese men 
are less likely to be recommended for biopsy, thereby lowering the number of cancers 
detected in this group. Finally, obese men tend to present with larger prostates than do 
non-obese men (7, 45, 46). Larger prostate volumes make prostate needle-biopsy more 
difficult and, as a result, may result in a lower probability of cancer detection. The 
combined effects of obesity on performance of DREs, PSA level, and prostate volume 
may lead to appreciable detection bias when estimating the effect of obesity on prostate 
cancer. Prostate cancer detection begins with a physical exam that includes a DRE and 
PSA test due to symptoms, or a PSA in asymptomatic men as part of screening. The 
results of these tests define the process of cancer  detection, which is illustrated in Figure 
11 
1.2. Determining how these tests are affected by obesity and what role prostate volume 









Diabetes and Prostate Cancer 
The association between diabetes and prostate cancer risk has been studied in 
several epidemiologic studies, and the consensus is that a reduction in risk is associated 
with type 2 diabetes. In their recent meta-analysis, Kasper and Giovannucci (47) found 
that the majority of the evidence supports a reduction in prostate-cancer risk associated 
with type 2 diabetes. Two of the largest studies found reductions in risk ranging from 
approximately 10-47 percent (38, 48). Results from several smaller studies, however, 
have been mixed with some reporting positive associations. These inconsistencies may be 
attributable to changes in insulin action over the course of diabetes. As noted above, type 
2 diabetes is a complex metabolic disease characterized initially by insulin resistance and 
hyperinsulinemia. However, with increasing duration of the disease, the pancreas loses its 
ability to create insulin because of damage to the pancreatic B cells and circulating levels 
Figure 1-2: The path to prostate cancer detection 
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of insulin decrease. Risk of prostate cancer has been associated with high circulating 
levels of insulin and insulin resistance. Consequently, it has been hypothesized that the 
incidence rate of prostate cancer increases among men recently diagnosed with diabetes, 
but then subsequently declines when insulin levels decrease (ignoring the effect of 
aging). In support of this hypothesis, investigators from the Cancer Prevention Study 
Nutrition Cohort, a prospective study of cancer incidence and mortality among 184,192 
US men and women, reported that prostate-cancer incidence was higher among men 
recently diagnosed with diabetes than among men of the same age with diabetes 
diagnosed several years earlier (49). Furthermore, diabetic men have been found to have 
a 20% lower mean PSA level than do non-diabetic men (50, 51). As shown in figure 1.1, 
it is plausible, based on this evidence, that hyperinsulinemia influences sex-hormone 
signaling, which proliferates changes in the cell cycle that perpetuate prostate cancer cell 
growth. Taken together, these data provide compelling evidence that associations 
between diabetes duration and insulin resistance and prostate cancer biology exist. 
However, further research is necessary to understand what role diabetes plays in prostate 
cancer development as a comorbid condition in the metabolic syndrome. 
 
Hypertension and Prostate Cancer 
Research investigating the role hypertension plays in prostate cancer etiology is 
sparse. Hypertension was positively associated with prostate cancer diagnosis in the Flint 
Men’s Health Study, a population-based study of African American men, which was 
modeled after the OCS (52). Furthermore, a prospective cohort study of 29,364 
Norwegian men found that every 12 mm increase in blood pressure resulted in an 8% 
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increase in the incidence or prostate cancer (30). It is plausible that hypertension 
increases the risk of prostate cancer through sympathetic nervous system activity that can 
result in androgen-mediated stimulation of prostate cancer growth (53). 
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Specific Aims and Hypotheses 
  Prostate cancer and metabolic syndrome and its components, T2DM and obesity, 
are common comorbid conditions that bring millions of older American men to medical 
attention each year. Although results from epidemiologic studies have suggested that 
metabolic syndrome, diabetes and obesity may be risk factors for prostate cancer, no 
clear consensus has been reached.  As these conditions become more prevalent, it is 
crucial not only to gain a better understanding as to how metabolic syndrome and its 
components affect prostate cancer risk, but also to understand the extent to which those 
factors influence disease detection.  Furthermore, the majority of the conclusions in this 
field, to date, have been drawn from cross-sectional studies of prevalent cases and case-
control studies that rely on recall of past weight ; and most have neglected the role of 
prostate volume on outcome. Therefore, the goal of this dissertation was estimate the 
effects of metabolic syndrome, T2DM, hypertension, and obesity on prostate-cancer risk 
and detection, while accounting for the influence of prostate volume, disease stage, PSA 
levels, and hormone levels. I accomplished this research goal by addressing five specific 
aims. 
Specific Aims   
1. To test the hypothesis that the metabolic syndrome and its components (type 2 
diabetes, hypertension and obesity) affect the risk of prostate cancer in middle-aged 
and older Caucasian men. (Chapter 2) 
 
2. To test the hypothesis that diabetes and hypertension lower PSA levels in men at risk 
of prostate cancer. (Chapter 3) 
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3. To test the hypothesis that obesity or increases in obesity lower PSA levels in men at 
risk of prostate cancer.  (Chapter 4) 
 
4. To test the hypothesis that the obesity and PSA association is influenced by detection 
issues involving the plasma hemodilution of PSA and increasing prostate volumes. 
(Chapter 4) 
 
5.    To test the hypothesis that the metabolic components decrease the risk of prostate 
biopsy in men at risk of prostate cancer and decrease the risk of a positive prostate biopsy 
among 519 men who received biopsies during follow-up. (Chapter 5) 
 
With the incidence of metabolic diseases reaching epidemic proportions in the 
United States, elucidating the associations between metabolic syndrome and its 
components with prostate cancer risk and detection would have striking implications for 
the health of the aging male population. Findings from this study will set the direction for 
the next set of investigations to elucidate these associations and provide clues to 
understanding the etiology, as well as shape detection strategies for prostate cancer in 
men with these metabolic conditions.  
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Chapter 2  
The Effects of Metabolic Conditions on Prostate Cancer Incidence over 15 Years of 
Follow-up: Results from the Olmsted County Study 
 
Abstract 
Objective: Research on the possible role of the metabolic syndrome in the etiology of 
prostate cancer has yielded inconsistent results. Combining multiple components of the 
syndrome into a single variable may obscure the separate and combined effects of these 
metabolic components on prostate cancer risk. The goal of this study was to determine if 
combinations of obesity, hypertension, and diabetes influence the development of 
prostate cancer over 15 years of follow-up.  
Methods: In 1990, a randomly selected cohort of Caucasian men from Olmsted County, 
Minnesota, ages 40-79, was recruited; 2,445 completed a questionnaire that included 
physician-diagnosed diabetes and hypertension. Anthropometric measures were collected 
during clinical examination. Biopsy-confirmed prostate cancer was identified from 
medical records. Proportional hazards regression was used to estimate the effects of these 
metabolic conditions, both individually and in combination, on the incidence rate of 
prostate cancer.  
Results: Men with hypertension alone or in combination with diabetes were more likely 
to develop prostate cancer than were men without any of the metabolic conditions. The 
metabolic syndrome—the presence of all three conditions compared to men with no 
17 
metabolic components—was only minimally and inversely associated with prostate 
cancer (HR: 0.81; 95% CI: 0.20, 3.3) and no monotonic association between the number 
of metabolic components and prostate cancer was observed.  
Conclusions: Our results suggest that it may not be sufficient to treat metabolic 
conditions as one variable when investigating the etiology of prostate cancer in Caucasian 
men. Further research should focus on the separate and combined effects of these 




Prostate cancer is the most common non-cutaneous cancer among American men 
and the second leading cause of cancer death among men in the United States (54). The 
incidence of this disease is estimated to exceed 192,000 cases among American men in 
2009 (2).  
The metabolic syndrome, a cluster of conditions including type 2 diabetes, 
dyslipidemia, hypertension and obesity, is also a highly prevalent condition in the aging 
US population with overall prevalence in US adults estimated to be 25% (6). The main 
components of the metabolic syndrome, type 2 diabetes, hypertension, and obesity are 
arguably reaching epidemic proportions in the United States, resulting in significant 
morbidity and bringing millions of men to medical attention each year. Currently, 34% of 
US adults, age 20 and over, are described as obese (55); 31% suffer from high blood 
pressure (4); and 18 million adults are reported to currently have type 2 diabetes (23, 56). 
Recently, several groups of investigators have suggested that features of the 
metabolic syndrome may be predictive of prostate cancer risk. Specifically, men with 
more than three components of the metabolic syndrome in a prospective study of 16,209 
men were 1.5 times more likely to be diagnosed with prostate cancer in the 27 years of 
follow-up than were men with no metabolic syndrome components (26). Hammarstan et 
al. found that men with disseminated (T3) prostate cancer were more likely than men 
with localized (T2) disease to have multiple components of the metabolic syndrome (27). 
Furthermore, a prospective study of Finnish men found that men with the metabolic 
syndrome have a 2-fold increased risk of prostate cancer, and that the risk was greater in 
men with a body mass index (BMI) greater than or equal to 27 kg/m2 compared to the 
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risk in men with a BMI less than 27 kg/m2 (28). These results are in conflict with a recent 
prospective study that found little to no evidence that metabolic syndrome or its 
components were associated with prostate cancer in 29,364 Norwegian men followed for 
an average 9.3 years (30).  
Each of the primary components of the syndrome--diabetes, obesity and 
hypertension--have been found to be associated with prostate cancer. While large 
population-based studies have shown that body mass index is positively associated with 
the incidence of prostate cancer (31-33, 36), more recent studies have found either no 
association or an inverse association between obesity and prostate cancer incidence (35, 
47, 57). It is unclear, however, whether these findings reflect the effect of obesity on the 
risk of prostate cancer, the prognostic effect of obesity on prostate cancer progression, or 
the effect of obesity on detection of the disease.  
Evidence of the association between type 2 diabetes and prostate cancer yields 
conflicting findings; results may reflect the changing action of insulin over the course of 
diabetes progression. A recent meta-analysis found that the majority of the evidence to 
date supports a reduction in prostate cancer risk associated with type 2 diabetes (52). 
Previous work assessing the association between hypertension and prostate cancer is 
sparse; however, the presence of hypertension may increase the risk of prostate cancer 
(30). 
It is unclear, however, whether combining these conditions into one syndrome is 
an appropriate approach when investigating the etiology of prostate cancer. Specifically, 
combining multiple components of the syndrome into a single variable may confound or 
obscure the separate effects and interactions of these metabolic components on prostate 
20 
cancer risk. Therefore, the goal of this study was to determine whether obesity, 
hypertension, and diabetes alone and in combination, influence the incidence of prostate 
cancer over 15 years of follow-up. 
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Materials and Methods 
Subject Selection  
The Olmsted County Study (OCS) of Urinary Symptoms and Health Status 
among Men is a longitudinal, population-based investigation of Caucasian men, residing 
in Olmsted County, MN (58, 59). In 1990, a random sample of men 40-79 years old, as 
enumerated by the Rochester Epidemiology Project, was screened for inclusion (60). 
Men with a history of prostate or bladder surgery, urethral surgery or stricture, or medical 
or neurological conditions that affect normal urinary function were excluded. Eligible 
men (n=3,874) were invited to take part in the study, and 2,115 (55%) agreed to 
participate. Participants completed a previously validated baseline questionnaire that 
ascertained information on urinary symptoms, medical histories, and various 
demographic and behavioral characteristics. A 25% random subset of the total cohort was 
invited to participate in a detailed urologic clinical examination. Of the 537 randomly 
selected men, 475 (88%) agreed to participate in the clinical portion of the study. 
Since 1990, the cohort has been followed biennially using a similar questionnaire 
to that used at baseline. During the second and third rounds of visits, men who did not 
participate in the follow-up were replaced by randomly selected eligible men from the 
community (n=332 total cohort; n=159 clinic cohort). After the third round, the study has 
been maintained as a fixed cohort.  
Measurements 
Biopsy-confirmed cases of prostate cancer were identified through detailed 
review of medical records, yielding a total of 206 cases. Information on self-reported 
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physician-diagnosed type 2 diabetes, and high blood pressure was collected at baseline. 
Men who reported using antihypertensive medication prior to baseline or who reported a 
physician diagnosis of hypertension at baseline were considered hypertensive for this 
analysis. Men that reported diabetes at baseline were considered diabetic. A trained 
research assistant measured height and weight, and BMI was calculated by dividing the 
weight in kilograms by the height in meters squared. Men with a BMI greater than or 
equal to 30 kg/m2 were considered obese, based on the definition established by the 
World Health Organization (WHO) (55).  
Metabolic syndrome was defined using a modified version of the WHO definition 
(17) and focused on the three components measured at baseline: self-reported type 2 
diabetes, self-reported diagnosis of hypertension and/or use of antihypertensive 
medication prior to baseline, and measured obesity at baseline. 
Potential confounders and effect modifiers included in these analyses were family 
history of prostate cancer based on self-reported first degree relative with physician-
diagnosed prostate cancer, non-steroidal anti-inflammatory drug (NSAID), 5-alpha 
reductase inhibitor (5-ARI) or statin use prior to baseline, household income, years of 
education, and age at baseline.  
Statistical Analysis 
 Incidence rates of prostate cancer were estimated for the total cohort and by 
category of selected demographic, medical history and metabolic component status by 
dividing the number of incident prostate cancer cases by the amount of person-time at 
risk. Participants’ person-time contribution began on the date they completed their 
baseline questionnaires and ended at the diagnosis of prostate cancer or the last date of 
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passive surveillance chart review, whichever came first. The associations of 
sociodemographic characteristics and baseline metabolic conditions with prostate cancer 
were described using crude incidence rates. Age-adjusted hazard (incidence rate) ratios 
and 95% confidence intervals measuring the associations between the metabolic 
characteristics and prostate cancer incidence were estimated using Cox proportional 
hazards regression (SAS procedure proc phreg). The proportional hazards assumption 
was assessed using Schoenfeld residuals as well as an interaction term with time and not 
found to be violated for the three metabolic components. The effects of the various 
combinations of the metabolic conditions, as well as their interactions, on prostate cancer 
risk were assessed using multivariable Cox models adjusting for age. Equations used in 
this analysis are displayed in Appendix 1. All statistical analyses were performed using 
SAS 9.2 software (SAS Institute, Cary, NC). 
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Results 
Among this cohort of Caucasian men, 206 cases of prostate cancer were detected, 
and the estimated incidence rate was 6.88 per 1,000 per year. Prostate cancer was 
positively associated with age (Table 2-1; p for trend <0.001). The incidence rate of 
prostate cancer was greater in men with a family history of prostate cancer than in men 
without a family history of prostate cancer (p<0.001). Also, men who achieved more 
education and earned more income had lower incidence rates of prostate cancer when 
compared to men with less education (p for trend=0.0005) and income (p for 
trend=0.0008) (Table 2-1). 
 Table 2-2 displays the crude and age-adjusted hazard ratios for each metabolic 
variable, unadjusted for the others. Men with a history of diabetes did not have an 
elevated rate of prostate cancer (Table 2-2). Hypertensive men were 1.5 times more likely 
to develop prostate cancer than were non-hypertensive men (hazard ratio (HR): 1.5; 95% 
confidence interval (CI): 1.1, 2.0), although this association was attenuated when 
adjusted for age (HR: 1.1; 95% CI: 0.79, 1.4). An increasing number of metabolic 
components were not consistently associated with prostate cancer incidence, adjusting for 
age (Table 2-2). Those with one component had a slightly increased rate, while those 
with two or three components had a slightly decreased rate of prostate cancer. 
Adjustment for age, family history of prostate cancer and baseline statin use did not 
change these results, nor did adjustment for age, family history of prostate cancer, 
baseline statin use, education and income (data not shown). 
 Despite small numbers of cases, the combined categories of the three conditions 
were also examined. Figure 2-1 displays the unadjusted hazard ratios and age-adjusted 
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hazard ratios of prostate cancer for all eight combinations of the three components of the 
metabolic syndrome. Compared to men with no components of the syndrome, men with 
all three--the metabolic syndrome--did not have an elevated rate of prostate cancer, 
adjusting for age (HR: 0.81; 95% CI: 0.20, 3.3); however, this estimate is imprecise 
because there were only two cases diagnosed in the group with all three conditions. The 
presence of diabetes alone was inversely associated with prostate cancer (age-adjusted 
HR: 0.62; 95% CI: 0.15, 2.5), but men who were hypertensive, diabetic and not obese 
were more likely to develop prostate cancer compared to men who did not have any of 
the three conditions (age-adjusted HR: 1.3; 95% CI: 0.53, 3.2). Obesity and hypertension 
alone were associated with an increased risk of prostate cancer; however, the 
combination of the two was associated with a decreased risk of prostate cancer compared 
to men with none of the conditions (age-adjusted HR: 0.50; 95% CI: 0.23, 1.1) (Figure 2-
1).  
In further examination of the interaction between obesity and hypertension, the 
only notable departure from multiplicative effects in the proportional hazards model was 
the interaction between obesity and hypertension (p = 0.013) (Table 2-3). The estimated 
hazard ratio, comparing men with both conditions to men with neither condition, was 
0.69 (95% CI: 0.35, 1.4). In contrast, the estimated hazard ratio for men with only 
hypertension was 1.8 (95% CI: 1.3, 2.5). 
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Discussion 
 In this prospective study of 2,445 Caucasian men ages 40-79, the metabolic 
syndrome, defined as the presence of obesity, hypertension and type 2 diabetes, was 
minimally and inversely associated with the development of prostate cancer over 15 years 
of follow-up. However, the components of the metabolic syndrome alone were 
differentially associated with the rate of prostate cancer. After adjustment for age, the 
presence of only hypertension was associated with an increased rate of prostate cancer. 
The combinations of components were also found to influence the rate of prostate cancer 
differently, as men who were hypertensive and obese were less likely to develop prostate 
cancer and men who were diabetic and hypertensive were more likely to develop prostate 
cancer, adjusting for age. Obesity modified the association between hypertension and 
prostate cancer, as men who were obese and hypertensive were less likely to develop 
prostate cancer, while men who were hypertensive alone were more likely to develop 
prostate cancer compared to men who did not have either condition. 
The association between diabetes and prostate cancer risk has been studied in 
several epidemiologic studies. In their recent meta-analysis, Kasper and Giovannucci 
found that the majority of the evidence supports a reduction in prostate cancer risk 
associated with type 2 diabetes (47). A weak inverse association between diabetes and 
prostate cancer was also observed in the current study, but it may have been a chance 
finding. Alternatively, our findings may obscure the changing association between insulin 
level and prostate cancer risk over the course of diabetes progression. Insulin levels are 
initially high in type 2 diabetes but fall over time due to the damage to the pancreatic ß 
cells. Therefore, the relation between diabetes and prostate cancer may change from 
27 
positive to inverse as diabetes progresses. This explanation is supported by research 
suggesting that men with early-stage diabetes have an increased risk of prostate cancer 
while men with later stage disease have a decreased risk (49, 61). Unfortunately, we did 
not have information on insulin levels or the duration of diabetes in our database, and we 
observed only 9 cases of prostate cancer among diabetics. 
Obesity (BMI ≥30 kg/m2) was minimally and inversely associated with prostate 
cancer in this cohort when compared to a BMI of less than 30 kg/m2. Our results are 
consistent with previous studies, suggesting either no association or an inverse 
association between obesity and prostate cancer incidence (35, 47, 57). In addition, 
obesity has been differentially associated with aggressive versus non-aggressive prostate 
cancers; a reduced risk of low-grade disease and an increased risk of high-grade disease 
have been observed for obese men (40, 62, 63). Our results, however, did not change 
when stratified by grade and stage of prostate cancer (data not shown).  
While other large, population-based studies have found obesity to be associated 
with an increased risk of prostate cancer, the current literature as a whole has yielded 
inconsistent results (31-33, 36). Several recent studies have suggested that detection bias 
associated with obesity may partly explain the inverse association between obesity and 
prostate cancer incidence (7). Obese men have lower prostate specific antigen (PSA) 
levels than do non-obese men, (8, 11) possibly due to decreased testosterone 
concentrations or a hemodilution effect as a result of increased prostate volumes (10). As 
a result, obese men are less likely to be recommended for biopsy based on their PSA 
levels. Furthermore, the difficulty of detecting cancer upon biopsy is increased due to the 
larger prostate volumes (10, 11), thereby lowering the number of cancers detected in this 
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group. While it is plausible that obesity can influence the growth of prostate cancer 
through the action of adipocytes, it is unclear if the associations seen in this study and in 
previous work are biased due to detection issues that occur among obese men. 
Research investigating the role hypertension plays in prostate cancer etiology is 
very sparse. Hypertension was positively associated with the rate of prostate cancer in 
this study, which is similar to results found in the Flint Men’s Health Study, a population-
based study of African American men that was modeled after the OCS (52). Also, a 
prospective cohort study of 29,364 Norwegian men found that every 12 mm increase in 
blood pressure resulted in an 8% increase in the incidence or prostate cancer (30). It is 
plausible that hypertension could increase the risk of prostate cancer through sympathetic 
nervous system activity that can result in androgen-mediated stimulation of prostate 
cancer growth (53). Men with both hypertension and obesity had a lower rate of prostate 
cancer in our study compared to men with neither condition, and men with hypertension 
who were not obese were at increased risk. This apparent heterogeneity of effects may be 
influenced by the likelihood of these men receiving biopsies. Specifically, it is possible 
that men with both comorbidities are less likely to be biopsied, as a result of physician 
perception that these comorbidities are more life threatening than prostate cancer.  
In the current study, little association was seen between the presence of all three 
components of metabolic syndrome and prostate cancer. While we did observe an 
association between the presence of one component and an increase in the rate of prostate 
cancer adjusting for age, an increasing number of components was not found to be 
positively and consistently associated with prostate cancer. These results seem to conflict 
with previous population-based studies that found more than three components of the 
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metabolic syndrome were associated with an increased risk of prostate cancer (26-28). 
The discrepancy in results may in part be due to the varying definitions of metabolic 
syndrome used in the current and previous investigations (i.e., three vs. more than three 
components of the metabolic syndrome) or to the small number of cases detected among 
men with all three components. Additionally, the definitions of metabolic syndrome 
recommended by the WHO and Adult Treatment Panel III were used in previous 
investigations, but our study focused on the combination of the components rather than 
the syndrome alone. It is also possible that the differing results are due to the 
unaccounted influence of dyslipidemia on prostate cancer risk in the OCS.  
Our results, however, are consistent with those of Tande et al. (25), who found 
men with at least three out of the five metabolic syndrome components were 
approximately 25% less likely to develop prostate cancer. Men who had two or three 
components had a slightly decreased risk of prostate cancer compared to those who had 
no components of the metabolic syndrome. It is possible that the metabolic syndrome 
reduces the risk of prostate cancer through the action of sex hormones. The cross-talk 
between androgens, sex hormone-binding globulin and insulin is thought to influence 
prostate cancer (26), and men with metabolic syndrome exhibit decreased testosterone 
levels (64), thus potentially decreasing their risk of prostate cancer. It is also possible that 
these results are explained in part by a detection bias that results in a lower rate of 
prostate cancer among obese men.  
The current study utilized a large, ongoing cohort of Caucasian men, which 
included 15 years of follow-up to date. However, there are several limitations that must 
be considered. First, the baseline measures of diabetes and hypertension do not account 
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for changes in these conditions over time. Furthermore, ages at diagnosis of diabetes and 
hypertension are not available in this cohort and thus limit our ability to make inferences 
about the progression of these conditions. Finally, while we are limited in our reliance on 
self-report of several metabolic conditions, diabetes diagnosis was validated among self-
reported cases in a larger cohort study of diabetes in Olmsted County from 1950 to 2000 
(65). 
Although the long follow-up period lends itself to problems associated with 
attrition, previous work in this cohort found that participant dropout was not associated 
with diabetes, hypertension, or PSA level after adjustment for age, thus suggesting the 
potential impact of this bias may be limited (66). Also, because this is a Caucasian 
sample of men, generalizing these findings to other racial groups may not be appropriate. 
The incidence rate of prostate cancer as well as the prevalence of the components of 
metabolic syndrome are thought to differ by race (9, 67); therefore, our effect estimates in 
Caucasians may not be applicable to other racial groups with different incidences of these 
conditions. However, the methods used in this study to estimate the effects of metabolic 
conditions on the incidence of prostate cancer can be applied to other populations from 
diverse settings. Finally, it is possible that our results were influenced by the detection 
bias that is thought to exist in obese men.   
In summary, we assessed whether different combinations of metabolic conditions 
confer different risks of prostate cancer. Men who were hypertensive and obese had a 
lower incidence rate of prostate cancer than did men without either condition, though this 
association was imprecisely estimated and may have been influenced by detection bias, 
as noted earlier. However, men with hypertension alone were at increased risk of disease, 
31 
suggesting that the different combinations of these metabolic conditions may affect 
prostate cancer incidence differently. Explanations as to why these conditions may 
differentially influence prostate cancer risk remain unclear. Previous work dealing with 
the influence of the overall metabolic syndrome on prostate cancer etiology may have 
obscured the separate and combined effects of the conditions it includes. Future studies, 
therefore, should examine the individual components of the metabolic syndrome in 
addition to combining them into a single variable; however, large samples will be needed 
to achieve sufficient precision and power.  
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Age at baseline     <0.01/<0.01   
  40-49 33 13743 2.40  1 -- 
  50-59 63 8076 7.80  3.2(2.1, 4.9) -- 
  60-69 71 5511 12.88  5.4(3.6, 8.1) -- 
  70+ 39 2633 14.81  6.3(4.0, 10.1) -- 







  No 169 27224 6.21  1 1 
  Yes 37 2739 13.51  2.2(1.5, 3.1) 2.0(1.4, 2.9) 
5-ARI use    0.58   
  No 205 29882 6.86  1 1 
  Yes 1 81 12.38  1.8(0.26, 13.1) 1.5(0.21, 10.8) 
NSAID use    0.55   
  No 158 23505 6.72  1 1 
  Yes 48 6458 7.43  1.1(0.80, 1.5) 0.79(0.57, 1.1) 
Statin use     0.82   
  No 199 28756 6.92  1 1 
  Yes 7 1206 5.80  0.83(0.39, 1.8) 0.67(0.32, 1.4) 
Education    <0.01/<0.01   
  Less than high school graduate 36 2604 13.83  1 1 
  Finished high school/some   





 0.47(0.32, 0.69) 0.78(0.52, 1.2) 
  College degree and beyond 68 11698 5.81  0.42(0.28, 0.62) 0.84(0.55, 1.3) 
Marital status    0.90   
  Single, divorced, widowed, separated 23 3038 7.57  1 1 
  Married/living together 183 26833 6.82  0.89(0.58, 1.4) 0.79(0.51, 1.2) 
Salary    <0.01/<0.01   
  <$25,000 58 5148 11.27  1 1 
  $25,000-$44,999 62 8786 7.06  0.62(0.43, 0.88) 0.82(0.57, 1.2) 
  $45,000-$64,999 31 7573 4.09  0.36(0.23, 0.55) 0.65(0.41, 1.0) 
  $65,000+ 47 7226 6.51  0.57(0.39, 0.84) 1.1(0.74, 1.7) 
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Diabetes diagnosis at 
baseline 
     
  No  197 28764 6.85 1  1  
  Yes 9 1198 7.51 1.1(0.57, 2.2) 0.77(0.39, 1.5) 
Hypertensive at 
baseline  
     
  No 140 22832 6.13 1 1  
  Yes 66 7130 9.26 1.5(1.1, 2.0) 1.1(0.79, 1.4) 
Obesity      
  Not Obese (<30 kg/m2) 169 23316 7.25 1 1  
  Obese (≥30 kg/m2) 36 6228 5.78 0.80(0.56, 1.1) 0.88(0.61, 1.3) 
Number of metabolic 
syndrome components 
     
  0 111 18348 6.05 1 1 
  1 81 8974 9.03 1.5(1.1, 2.0) 1.3(0.96, 1.7) 
  2 or 3 14 2641 5.30 0.88(0.50, 1.5) 0.65(0.37, 1.1) 
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*Corresponds to a two-sided test of the null hypothesis that the effects of hypertension and 


















Hypertension No Hypertension  
HR (95% CI) HR (95% CI) 
 
 p-value* 
Obese 0.69(0.35, 1.4) 1.1(0.70, 1.6) 0.013 
Not Obese 1.8(1.3, 2.5) 1  
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Figure 2-1: Comparison of prostate cancer incidence among all 8 combined categories of 
three metabolic syndrome components, shown as a Venn diagram 
 
 
-Diabetes is defined as self-reported physician-diagnosed diabetes at baseline.  
-Obesity was calculated using the measured height and weight from the clinic 
examination, with those ≥30 kg/m2 classified as obese.  
-Hypertension was defined as those with high blood pressure at baseline or who reported 
using anti-hypertensive medication prior to baseline. 




Chapter 3  
The Effects of Type 2 Diabetes and Hypertension on Changes in Serum Prostate 
Specific Antigen Levels: Results from the Olmsted County Study 
 
Abstract 
Objective: Men with type 2 diabetes have lower concomitant prostate-specific antigen 
(PSA) levels; however, the influence of metabolic conditions on PSA changes over time 
remains unknown. Therefore, the goal of this study was to assess associations between 
type 2 diabetes and hypertension and changes in serum PSA levels.  
Methods: In 1990, a randomly selected cohort of Caucasian men, ages 40-79, from 
Olmsted County, MN completed questionnaires ascertaining demographic characteristics, 
current medical conditions and medications biennially, with a subset undergoing blood 
draws. Men with a physician diagnosis of diabetes or hypertension at baseline, or who 
reported using medications to treat these conditions prior to baseline were considered 
exposed. Men with at least two serum PSA measurements (n=569) and no history of 
prostate cancer were included in this analysis. Linear mixed models were used to estimate 
the annual percent change in serum PSA levels associated with diabetes and 
hypertension, adjusting for baseline age. 
Results: The overall mean change in serum PSA levels was 3.6% per year and increased 
with age (p=0.009).  Men with diabetes experienced less annual change in serum PSA 
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levels (1.1%) than did non-diabetic men (3.7%), adjusting for age (p=0.02). Age-adjusted 
change in serum PSA levels differed little by hypertension status (3.7% vs. 3.6%; 
p=0.49).  
Conclusions: Our results suggest that Caucasian men with type 2 diabetes experience 
smaller increases in serum PSA levels as they age compared to men without diabetes. 
Additional research is needed to elucidate whether this difference results in a relatively 
lower incidence of prostate cancer or less cancer detection among diabetic men. 
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Introduction 
Prostate cancer is the most common non-cutaneous cancer in U.S. men, with an 
estimated 192,280 new cases diagnosed in 2009 (68). While only 15% of men diagnosed 
with prostate cancer will ultimately die from it, the prevalence of clinically diagnosed 
disease remains high. Currently, prostate-specific antigen (PSA) is the most common 
screening test for prostate cancer with 58% of Caucasian men receiving an annual test 
(12). The low specificity of PSA testing and questionable benefit of PSA screening on 
prostate cancer mortality highlight the need for better detection strategies for prostate 
cancer ((15). Knowledge about the influence of concomitant comorbidities on serum PSA 
concentrations may improve the discriminant value of this test and reduce the number of 
unnecessary biopsies and subsequent overdiagnosis of indolent cancers. 
Type 2 diabetes and hypertension, two increasingly prevalent chronic diseases in 
the U.S., are arguably reaching epidemic proportions. It is estimated that 1 in 3 U.S. 
adults suffer from high blood pressure and 11% of U.S. men have type 2 diabetes (4, 55). 
Many studies have investigated the association between type 2 diabetes and prostate 
cancer, with the majority of evidence supporting an inverse association; the reported 
reduction in risk ranges from 10-40% in diabetics (47, 69). Previous findings also suggest 
that the effect of diabetes on prostate-cancer risk varies with the duration of diabetes; 
men with newly diagnosed diabetes have an increased risk, but as their diabetes 
progresses, their risk of prostate cancer declines (49). Furthermore, diabetes is associated 
with serum PSA levels; men with diabetes have approximately 10 to 20% lower 
concurrent serum PSA levels than do men without diabetes (50, 51). Similarly, elevated 
hemoglobin A1C levels are also inversely associated with serum PSA levels, and men 
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who use insulin and oral glucose medications have lower serum PSA levels than do men 
who do not use medications to treat diabetes (70). Taken together, these findings suggest 
that diabetes influences prostate-cancer risk and concurrent serum PSA levels.  
Studies evaluating the relationship between hypertension and prostate-cancer risk 
are more limited, with previous results suggesting that men with hypertension are more 
likely than men without hypertension to be diagnosed with prostate cancer (52). Research 
by Han and colleagues12 suggests that high blood pressure is positively associated with 
concurrent serum PSA levels.  
Although the results from these epidemiologic studies suggest that diabetes and 
hypertension may be associated with prostate cancer and concurrently influence serum 
PSA concentrations, they are limited by their cross-sectional designs. The effect of these 
conditions on serum PSA levels over time has yet to be characterized.  This is important 
as the change in serum PSA levels has been demonstrated to be more reliable in the 
detection of prostate cancer than single serum PSA measurements (71, 72). The 
increasing prevalence of hypertension and diabetes coupled with the increasing 
speculation regarding the reliable detection of prostate cancer with serum PSA levels 
make it crucial to gain a better understanding as to how these metabolic conditions 
influence prostate cancer detection. Therefore, the goal of this study was to determine the 
associations between type 2 diabetes and hypertension and longitudinal changes in serum 
PSA levels over 15 years of follow-up, using data from The Olmsted County Study 
(OCS) of Urinary Symptoms and Health Status among Men. 
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Materials and Methods 
The OCS of Urinary Symptoms and Health Status among Men is a longitudinal 
study of Caucasian men, residing in Olmsted County, MN ((58, 59). In 1990, a random 
sample of men 40-79 years old, as enumerated by the Rochester Epidemiology Project, 
was screened for inclusion (60). Men with a history of prostate or bladder surgery, 
urethral surgery or stricture, or medical or neurological conditions that affect normal 
urinary function were excluded. Also, men with diabetes who suffered from end-organ 
damage were excluded at baseline. Eligible men (n=3,874) were invited to take part in the 
study, and 2,115 (55%) agreed to participate. Participants completed a previously 
validated baseline questionnaire that ascertained information on urinary symptoms, 
medical histories, and various demographic and behavioral characteristics. A 25% 
random subset of the total cohort was invited to participate in a detailed urologic clinical 
examination, which included transrectal ultrasonography to determine prostate volume 
and serum PSA measurements. Of the 537 randomly selected men, 475 (88%) agreed to 
participate in the clinical portion of the study. 
Since 1990, the cohort has been actively followed biennially using a questionnaire 
similar to the one used at baseline. During the second and third rounds of visits, men who 
did not participate in the follow-up were replaced by randomly selected eligible men 
from the community (n=332 total cohort; n=158 clinic cohort). After the third round, the 
study has been maintained as a fixed cohort. Of the 633 men in the clinic cohort, men 
with at least two serum PSA measurements were included, and only serum PSA 
measurements obtained before prostate cancer diagnosis, BPH medication use or prostate 
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surgery/procedure were included. As a result, 569 men with 2,891 observations were 
included in this analysis (Figure 3-1).  
Measurements 
Information on self-reported physician-diagnosed type 2 diabetes, and high blood 
pressure was collected at baseline via questionnaire. Men who reported using 
antihypertensive medication prior to baseline or who reported a physician diagnosis of 
hypertension at baseline were considered hypertensive for this analysis. In addition, men 
who reported a physician diagnosis of diabetes at baseline or who used medication to 
treat diabetes prior to baseline were considered diabetic. Prostate volume, measured via 
transrectal ultrasonographic imaging, and serum PSA measurements were collected at 
each round of follow-up during the clinic examination.  
Potential confounders and effect modifiers assessed in these analyses include 
family history of prostate cancer based on a self-reported first-degree relative with 
physician-diagnosed prostate cancer, household income, years of education, age at 
baseline blood draw, prostate volume, and body mass index (BMI). Height and weight 
were measured by a trained research assistant, and BMI was calculated by dividing the 
weight in kilograms by the height in meters squared. Men with a BMI greater than or 
equal to 30 kg/m2 were considered obese, based on the definition established by the 
World Health Organization (WHO) (55). 
Statistical Analysis 
 Linear mixed effects regression models were used to estimate the annual percent 
change in serum PSA levels by regressing each measure on time from initial blood draw 
and adjusting for 10-year baseline age groups. Interaction terms with time were included 
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to allow for different slopes across these age groups. An overall annual change in serum 
PSA levels for each man was estimated by combining the average longitudinal change 
(fixed effects) with the individual changes (random effects). Additional models included 
terms for diagnosis of diabetes or hypertension and interaction terms to compare 
intercepts and slopes among those with and without a diagnosis. The mixed models used 
to estimate these parameters is shown in Appendix 2. Because of the skewed distribution, 
serum PSA levels were natural log-transformed, and therefore, annual changes represent 
percent changes per year assuming an exponential growth curve. Two-stage analysis was 
used to validate estimates of slopes from the mixed models. All statistical analyses were 




The 569 men in this sample were followed for a median of 8.4 years after baseline 
blood draw. The majority of men (91.2%) did not report a family history of prostate 
cancer. Twenty-five men (4.4%) reported type 2 diabetes at baseline, and 149 (26.2%) 
reported being hypertensive at baseline. The majority of men were not considered obese 
at baseline, as 425 (75%) men had a BMI less than 30 kg/m2 (Table 3-1). 
 In general, serum PSA levels increased over time as men aged in this cohort, as 
displayed in the observed and predicted values of serum PSA levels shown in Figure 3-2. 
Table 3-2 displays the annual percent changes in serum PSA levels from the linear mixed 
models. Overall, serum PSA levels in this cohort increased by 3.58% per year (p<0.001). 
The annual percent change in serum PSA levels increased with age (p=0.009), with men 
ages 70 and over at baseline experiencing the greatest annual percent increase in serum 
PSA levels (4.66%), followed by men ages 60-69 (4.64%), ages 50-59 (3.94%), and ages 
40-49 (2.59%) (Table 3-2). After adjusting for baseline age, baseline (intercept) serum 
PSA values were not different across diabetes status (p=0.65), or hypertension status 
(p=0.12) (results not shown).  After adjusting for age, men with diabetes at baseline 
experienced less of an annual increase in serum PSA levels than did men without diabetes 
(1.11 vs 3.68%; p=0.02) (Table 3-2).  Annual age-adjusted percent change in serum PSA 
levels did not differ by hypertension status (3.67% vs. 3.55%; p=0.49).  Figure 3-3 
displays the median predicted values in serum PSA levels during follow-up, by diabetes 
status. Additional results not discussed in this chapter are displayed in Appendix 2.  
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Discussion 
In this prospective cohort study of Caucasian men, ages 40-79, serum PSA levels 
increased at a rate of 3.6% per year.  Older men had more rapid increases in serum PSA 
levels compared to younger men, and men without diabetes had more rapid increases 
serum PSA levels compared to men with diabetes.  Hypertension, however, was not 
associated with rate of change in serum PSA levels.  
Although there are no other studies evaluating the impact of diabetes on changes 
in serum PSA levels over time, our finding that the change in serum PSA levels was 
associated with diabetes is consistent with previous cross-sectional findings suggesting 
that serum PSA levels are lower among diabetic men than among non-diabetic men. 
Specifically, Muller et al. found men with elevated and highly elevated hemoglobin A1C 
levels had 15% and 29% lower serum PSA levels, respectively. Men who were on insulin 
treatment and oral diabetic medications also had lower serum PSA concentrations (70). 
Using the National Health and Nutrition Examination Surveys, Werny and colleagues 
found 22% lower average serum PSA levels among men with type 2 diabetes ((50). 
These findings were further replicated by Fukui et al. (51) who observed 10 to 16% lower 
average serum PSA levels among male Japanese diabetics, ages 50-79 years. Our results 
suggest that men with diabetes have slower increases in serum PSA levels over time, and 
this might account for the lower serum PSA levels observed among diabetics in cross-
sectional studies. 
As noted in the introduction, the association between diabetes and serum PSA 
levels is hypothesized to vary with the duration of diabetes. Several studies have found an 
inverse relation between diabetes duration and serum PSA levels (49, 50). It is plausible 
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that as the duration of diabetes increases, the action of insulin decreases and testosterone 
increases, resulting in subsequent drops in serum PSA levels. This is supported by 
findings that later-stage diabetes is characterized by insulin resistance and lower levels of 
circulating insulin, which have been associated with lower prostate-cancer risk and serum 
PSA levels (49, 73). A lower risk in later-stage diabetes may be attributable to the 
androgen regulation of PSA levels. PSA cleaves insulin growth factor binding protein 3 
(IGFBP-3), a major binding protein for insulin growth factor 1 (IGF-1), which is 
involved in insulin signaling and associated with an increase in prostate-cancer risk (74, 
75). Previous findings that show use of diabetic medication is associated with serum PSA 
levels also support this hypothesis, as diabetic-medication use may be a proxy for 
diabetes severity (70).  
It remains to be demonstrated whether or not decreases in serum PSA levels drive 
the lower risk of prostate cancer observed among diabetic men in previous studies (47, 
76-78). If smaller increases in serum PSA levels among diabetics result in less detection 
of prostate cancer among asymptomatic cases, it might suggest a detection bias among 
diabetic men, similar to that thought to exist among obese men due to their lower serum 
PSA levels and increased prostate volumes (7, 42). Furthermore, if the smaller increase in 
serum PSA levels among diabetic men delays the diagnosis of prostate cancer, men with 
diabetes may be more likely to be diagnosed with later-stage disease. As such, the 
potential impact of diabetes on prostate-cancer detection warrants further investigation in 
future studies. 
 Hypertension was not associated with change in serum PSA levels over time in 
this cohort. Findings from previous studies suggest that hypertension is positively 
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associated cross-sectionally with serum PSA levels and longitudinally with the risk of 
prostate cancer (52, 73). Beebe-Dimmer et al. (52) found a positive association between 
hypertension and prostate cancer. Han et al. (79) found that diastolic blood pressure was 
positively associated with serum PSA levels in a sample of 38,356 Korean men. It is 
possible that androgen-mediated prostate-cancer growth is stimulated by increased 
sympathetic nervous-system activity subsequent to elevated blood pressure (53). The lack 
of an association between hypertension and change in serum PSA levels over time in our 
study may be in part due to the non-specificity of hypertensive medications or to 
hypertensive status being defined only at baseline. It is possible that some non-
hypertensive men were prescribed medication because of cardiovascular disease.  It is 
also plausible that men with hypertension in this cohort were being treated during follow-
up and therefore, the effect of hypertension on serum PSA levels is attenuated, resulting 
in a null association when compared to men without hypertension.  
While this study characterizes whether diabetes and hypertension influence 
change in serum PSA levels using a prospective cohort study with 15 years of follow-up, 
there are several potential limitations that need to be considered. First, the baseline 
measures of diabetes and hypertension do not account for changes in these conditions 
during follow-up, which might have influenced subsequent serum PSA levels. However, 
it is likely that not accounting for additional diabetics over time is attenuating the 
difference in change in serum PSA levels among this cohort. Additionally, age at 
diagnosis of diabetes and hypertension were not queried of men, thereby limiting our 
ability to make inferences about the progression of these conditions and serum PSA 
levels. While we are limited in our reliance on self-report of the metabolic conditions, 
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diabetes diagnosis was validated among self-reported cases in a larger cohort study of 
diabetes in Olmsted County from 1950 to 2000 (65) and most studies show a 
concordance between self-report and medical records for chronic conditions such as 
diabetes and hypertension (80, 81). Although the long follow-up period lends itself to 
problems associated with attrition, previous work in this cohort found that participant 
dropout was not associated with diabetes, hypertension, or  serum PSA levels after 
adjustment for age, thus suggesting the potential impact of this bias on these results may 
be limited (66).Finally, because this is a Caucasian sample of men, generalizing these 
findings to other racial groups may not be appropriate.  
In conclusion, our results suggest that type 2 diabetes may decrease the rate at 
which serum PSA levels change over time.  Lower levels of serum PSA as men age 
potentially influences their detection of prostate cancer. Thus, it is plausible that the 
presence of diabetes may lead to fewer prostate cancers being detected among this group. 
As screening guidelines are revised for prostate cancer, it may be prudent to take into 
consideration the presence of metabolic conditions. Future research should investigate the 
longitudinal impact of these metabolic conditions on prostate-cancer detection in larger, 



























































      *Total N for some characteristics is less than 569 due to missing data  
Characteristic N (%) 
Age, years  
  40-49 243(42.7) 
  50-59 151(26.5) 
  60-69 103(18.1) 
  70+ 72(12.7) 
Marital Status  
  Single, divorced, widowed, separated 56(9.8) 
  Married/living together 511(89.8) 
Education  
  Less than high school graduate 60(10.5) 
  Finished high school/some college 267(46.9) 
  College degree and beyond 239(42.0) 
Salary  
  <$25,000 98(17.2) 
  $25,000-$44,999 148(26.0) 
  $45,000-$64,999 153(26.9) 
  $65,000+ 143(25.1) 
Family history of prostate cancer  
  No 519(91.2) 
  Yes 50(8.8) 
Diabetes at baseline  
  No 544(95.6) 
  Yes 25(4.4) 
Hypertension at baseline  
  No 420(73.8) 
  Yes 149(26.2) 
BMI at baseline, kg/m2  
  <25 151(26.5) 
  25-29 274(48.2) 
  30-34 118(20.7) 
  ≥35 26(4.6) 
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*Age-adjusted slopes from mixed models. 
 Annual percent 
change in PSA 
Baseline Characteristic Mean, std. dev. 
Overall* 3.58, 2.96 
p-value <.0001 
Age  
40-49 2.59, 2.79 
50-59 3.94, 2.91 
60-69 4.64, 3.04 
70+ 4.66, 2.46 
p-value 0.009 
Diabetes*  
No 3.68, 2.94 
Yes 1.11, 2.76 
p-value 0.02 
Hypertension*  
No 3.55, 2.96  
Yes 3.67, 2.97  
p-value 0.49  
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Chapter 4  
The Effects of Body Mass Index on Longitudinal Changes in Serum Prostate 
Specific Antigen Levels and Prostate Volume over 15-years of Follow-up: 
Implications for Prostate Cancer Detection 
 
Abstract 
Objective: Body mass index (BMI) is inversely associated with prostate-specific antigen 
(PSA) level in cross-sectional analyses and positively, though inconsistently, associated 
with the diagnosis of prostate cancer.  It is not clear, however, whether these findings are 
due to the effect of obesity on the development or progression of prostate cancer or to the 
greater probability of disease detection among obese men with prostate cancer (detection 
bias).  There is little evidence about whether BMI affects change in PSA level and what 
other factors might explain the associations of obesity with PSA level and prostate 
cancer.  The goal of this study was to use longitudinal data to investigate the association 
of BMI and BMI change with change in PSA level and to assess the possible roles of 
PSA hemodilution and prostate volume in explaining the associations of obesity with 
PSA level and prostate-cancer diagnosis.   
Methods: In 1990, a randomly selected cohort of Caucasian men, ages 40-79, from 
Olmsted County, MN completed questionnaires ascertaining demographic characteristics, 
current medical conditions and medications biennially, with a subset undergoing blood 
draws and clinical exams during a 15-year follow-up period.  Our analyses were 
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restricted to 545 men with at least two PSA, BMI and prostate-volume measurements.  
Linear mixed models were used to predict the slopes and intercepts of individual changes 
in BMI, PSA, prostate volume, plasma volume, and PSA mass (the product of PSA 
concentration and plasma volume), adjusting for age.  Linear regression was then used to 
estimate the annual percent change in PSA associated with the predicted intercept and 
slope of BMI, adjusting for baseline PSA, baseline prostate volume, and rate of change in 
prostate volume. The mean predicted intercepts and slopes of PSA mass and plasma 
volume were compared across baseline BMI categories. 
Results: Baseline BMI was inversely associated with the annual percent change in PSA, 
adjusting for age, baseline PSA, and prostate volume and the rates of change in BMI and 
prostate volume (β=-0.003, 95% CI: -0.006, -0.0003).  A baseline BMI ≥ 30kg/m2 (vs. < 
30kg/m2) was associated with a 0.09% annual increase in prostate volume after 
adjustment for age (β=0.09, 95% CI: 0.03, 0.015).  Baseline obesity was positively 
associated with mean baseline levels and the rate of change in plasma volume (both p 
<0.001).  Both the mean baseline values and the rate of change in PSA mass were similar 
when compared across categories of baseline BMI.  
Conclusions: Baseline obesity was associated with the rate of change in both PSA and 
prostate volume in a cohort of white men followed for 15 years.  Our results suggest that 
the inverse association of obesity with prostate–cancer diagnosis is at least partly due to 
detection bias, which is due to larger prostate volumes and PSA hemodilution in obese 
men.  Future research should focus on further elucidating what role BMI plays in the 
detection of prostate cancer in other racially heterogeneous populations. 
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Introduction 
Prostate cancer is the most common non-cutaneous cancer in U.S. men, with an 
estimated 192,280 new cases diagnosed in 2009 (2).  Prostate specific antigen (PSA) 
currently is the most common screening test for prostate cancer with 58% of Caucasian 
men receiving an annual test (12). The low specificity of PSA testing and questionable 
benefits of PSA screening on prostate cancer mortality highlight the need for better 
detection strategies for prostate cancer (15). Knowledge of the influence of concomitant 
comorbidities on serum PSA concentrations may improve the discriminant value of this 
test for predicting prostate cancer and reduce the number of unnecessary biopsies and 
subsequent overdiagnoses of indolent cancers. 
Obesity is a growing global epidemic, with more than half of the world’s adults 
categorized as being overweight and up to 30% categorized as obese (body mass index 
[BMI] ≥ 30) (19). In the US alone, 68% of adults are overweight or obese (3). Previous 
studies have implicated obesity in the development of prostate cancer, but the findings 
from these studies are inconsistent; large population-based studies found an increased 
risk of prostate cancer associated with obesity, (30-33) while other studies found either a 
null or inverse association between obesity and prostate cancer incidence.(34-36). 
Explanations for these inconsistencies include variations in the measurements of obesity 
between studies and at different times in the life course, differences in study design, 
insufficient assessment and control of confounders and effect modifiers, and different 
distributions of obesity in the study populations.  
Obesity is hypothesized to influence the detection of prostate cancer through its 
impact on prostate-cancer screening (7, 11). This hypothesis stems from the findings that 
56 
digital rectal examinations are more difficult to perform in obese men, which may lead to 
an increased number of missed diagnoses (11). Additionally, elevated serum PSA levels 
are considered a marker for prostate cancer presence; however, needle-biopsy is 
necessary for confirmation. Obese men have lower PSA levels than do non-obese men (8, 
10, 11), which may be due to decreased testosterone concentrations (7) and/or plasma 
hemodilution, the phenomenon that results from the dilution of soluble tumor markers 
being diluted by increased plasma volumes .(10). As a result, it is possible that obese men 
are less likely to be recommended for biopsy, thereby lowering the number of cancers 
detected in this group. Finally, obese men tend to present with larger prostates than do 
non-obese men (7, 11). Increased prostate volumes make prostate needle-biopsy more 
difficult and, as a result, may be lowering the number of prostate cancers detected. Thus, 
the combined effects of obesity on performance of digital rectal exams (DRE), PSA level, 
and prostate volume may lead to appreciable detection bias when estimating the effect of 
obesity on prostate cancer. 
Results from previous studies suggesting that obesity may be associated with 
serum PSA concentrations are limited by their cross-sectional designs, their failure to 
simultaneously account for other aspects of this potential detection bias, including 
prostate volume, and their inability to elucidate why this association exists. Furthermore, 
the estimated effects of baseline obesity and weight change on change in serum PSA 
level and prostate volume has yet to be characterized. Understanding these longitudinal 
associations is relevant because change in serum PSA level may be better than a single 
serum PSA measurement for prostate cancer screening (13) and therefore has important 
implications in terms of prostate cancer detection. The increasing prevalence of obesity 
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coupled with the increasing speculation regarding the reliable detection of prostate cancer 
with serum PSA levels make it crucial to elucidate how obesity influences the multiple 
facets of prostate cancer detection over time. Therefore, the goal of this study was to use 
longitudinal data to investigate the association of BMI and BMI change with change in 
PSA level and to assess the possible roles of PSA hemodilution and prostate volume in 
explaining the associations of obesity with PSA level and prostate-cancer diagnosis.   
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Materials and Methods 
Study population 
The Olmsted County Study (OCS) of Urinary Symptoms and Health Status 
among Men (OCS) is a longitudinal study of Caucasian men residing in Olmsted County, 
MN (58, 59). In 1990, a random sample of men 40-79 years old, as enumerated by the 
Rochester Epidemiology Project, was screened for inclusion (60). Men with a history of 
prostate or bladder surgery, urethral surgery or stricture, or medical or neurological 
conditions that affect normal urinary function were excluded. Eligible men (n=3,874) 
were invited to take part in the study, and 2,115 (55%) agreed to participate. Participants 
completed a previously validated baseline questionnaire that ascertained information on 
urinary symptoms, medical histories, and various demographic and behavioral 
characteristics. A 25% random subset of the total cohort was invited to participate in a 
detailed urologic clinical examination, which included prostate volume and serum PSA 
measurements. Of the 537 randomly selected men, 475 (88%) agreed to participate in the 
clinical portion of the study. 
Since 1990, the cohort has been actively followed biennially using a questionnaire 
similar to the one used at baseline. During the second and third rounds of visits, men who 
did not participate in the follow-up were replaced by randomly selected eligible men 
from the community (n=332 total cohort; n=159 clinic cohort) (Figure 4-1). After the 
third round, the study has been maintained as a fixed cohort. Of the 2,447 men in the 
OCS, 634 men participated in the clinic cohort after 8 rounds of follow-up, of which 552 
men with at least two PSA, body mass index and prostate volume measurements were 
included. Measurements of PSA level and prostate volume were censored after diagnosis 
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of prostate cancer, prostate surgeries and procedures, and use of any medications 
(prescription and herbal) for treatment of benign prostatic hyperplasia (BPH). As a result, 
545 men were included in this analysis, of which 544 men (2,805 observations) had 
information on PSA, 545 men (2,837 observations) had BMI information, and 543 men 
(2,687 observations) had information on prostate volume. 
Measurements 
BMI, prostate volume, and PSA were collected at each round of follow-up during 
the clinic examination. A trained research assistant measured height and weight, and BMI 
was calculated by dividing the weight in kilograms by the height in meters squared. Men 
with a BMI greater than or equal to 30 kg/m2 were considered obese, based on the 
definition established by the World Health Organization (WHO) (55). Prostate volume, 
was measured via transrectal sonographic imaging, and serum PSA levels were 
determined with the Tandem-R PSA assay (Hybritech Inc, San Diego, CA, USA). Body 
surface area, plasma volume and PSA mass was estimated using the following 
established formulas: Body Surface Area (m2)= body weight (kg)0.425 x  height (m)0.725 x 
0.2025 (82), Plasma Volume (L) = Body Surface Area (m2)  x 1.670 (83) and PSA mass = 
PSA (ng/mL) x Plasma Volume (10). Demographic information including household 
income, years of education and age at baseline blood draw were collected via 
questionnaire.  
Statistical Analysis 
 The cross-sectional associations between baseline obesity and participant 
demographics at baseline were tested using chi-square tests for association and Cochran-
Armitage tests for trend where appropriate. The distributions of baseline values and 
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predicted rates of change of PSA, BMI and prostate volume were determined overall and 
across 10-year age groups using medians and interquartile ranges. The associations of 
both the baseline values and predicted rates of change with age were tested using the test 
for trend from linear regression. Crude cross-sectional associations between BMI and 
PSA, BMI and prostate volume and prostate volume and PSA at each round of follow-up 
were also estimated using linear regression.  
Linear mixed-effects models were used to examine the association of baseline 
obesity with annual percent change in PSA and annual percent change in prostate 
volume. These models included age and a categorical measure for obesity (BMI<30, BMI 
≥30) as well as an interaction (product) term between obesity and time to compare the 
slope of PSA among those who were obese and not obese. The mixed model used to 
estimate these parameters is shown in Appendix 3 (Equation 1). Additional models were 
fit to assess the association of baseline BMI (treated as continuous), baseline BMI based 
on the WHO cut-offs, and repeated measures of BMI with the annual percent changes in 
PSA and prostate volume.  
A longitudinal 2-step analytic approach was used to examine the associations of 
the individual intercepts and slopes of BMI and prostate volume with the annual percent 
change in PSA. First, the annual percent change in PSA, BMI and prostate volume were 
estimated by individually regressing each measure on time from initial blood draw and 
age (10-year categories) using linear mixed-effects regression models. Interaction 
(product) terms were included to allow for different slopes across these age groups. Fixed 
and random effects were included to reflect both the mean effect and allow for individual 
variation in the baseline intercept and change over time.  An overall annual change in 
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each measure for each man was estimated by combining the average longitudinal change 
in time (fixed effects) with the individual changes (random effects). Similarly, both fixed 
and random effects allowed determination of an overall baseline intercept for each age 
decade and allowed for offsets for individual variation. The models used to conduct these 
analyses are included in Appendix 3 (Equations 2-4). Because of their skewed 
distributions, PSA level and prostate volume were log-transformed, and therefore, annual 
changes represent percent changes per year. The change in BMI reflects annual absolute 
changes.  
The second step of this approach was to estimate the effects of predicted 
intercepts of PSA, BMI and prostate volume and the predicted slopes of BMI and 
prostate volume on the predicted annual percent change in PSA (all derived from the 
mixed model in stage 1), using linear regression models adjusting for age. (Appendix 3, 
Equation 5)  
The adjusted predicted values of the intercepts and slopes of plasma volume and 
PSA mass were also estimated using linear mixed-effects regression models that 
individually regressed each measure on time from initial blood draw and age (10-year 
categories) and included a categorical measure for obesity (BMI<30, BMI ≥30), as well 
as an interaction term to compare the intercept and slope among those who were obese 
and not obese where appropriate. (Appendix 3, Equations 6-8) Because of the skewed 
distribution, PSA mass was log-transformed, and therefore, annual changes represent 
percent changes per year. The change in plasma volume reflects annual absolute changes. 
The means and standard deviations of the predicted slopes and intercepts of PSA mass 
and plasma volume from the mixed models were then compared across levels of age and 
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baseline obesity. All statistical analyses were performed using SAS 9.2 software (SAS 




In this cohort of Caucasian men, age was associated with obesity at baseline (p for 
trend 0.03) (Table 4-1).  Marital status, education and income differed little by baseline 
obesity status. Obese men more often reported a history of type 2 diabetes and a history 
of hypertension than did non-obese men at baseline (p= 0.006, 0.008). Baseline serum 
PSA levels differed slightly by baseline obesity status, such that men who were obese had 
a lower mean PSA level (1.13 ng/mL) compared to men who were not obese at baseline 
(1.37 ng/mL) (p=0.06). Prostate volume was similar when comparing obese to non-obese 
men at baseline. (Table 4-1) 
Table 4-2 displays the overall and age-specific distributions of the observed 
baseline values and predicted rates of change for BMI, PSA and prostate volume (derived 
from the mixed models). At baseline, the median BMI in the total sample was 27.03 
kg/m2 and was associated with age (p for trend = 0.07). Overall, the median serum PSA 
level at baseline was 0.90 ng/mL, and the median prostate volume was 25.57 grams. Both 
PSA and prostate volume were strongly and positively associated with age (p for trend 
<0.0001). The median rate of change in BMI was 0.14 kg/m2 per year and was non-
linearly associated with age (p for trend 0.001). The greatest median rate of change in 
BMI was seen among the youngest (40-49 years) and oldest (70+ years) men in this 
cohort. The median rate of change of PSA was 3.82% per year, and this change increased 
with age (p for trend <0.0001). The median annual percent change in prostate volume 
overall was 2.19%, and it was minimally associated with age. (Table 4-2) 
Cross-sectional analyses determined BMI to be weakly and inversely associated 
with PSA at each round of follow-up except at round 2. (Table 4-3) BMI was positively 
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but weakly associated with prostate volume cross-sectionally at each round of follow-up. 
Prostate volume was strongly and positively associated with PSA at each round of 
follow-up. (Table 4-3)  
Baseline obesity (BMI ≥ 30 kg/m2) was weakly inversely associated with the 
annual percent change in PSA (β= -0.07, 95% CI: -0.20-0.05), adjusting for age. Similar 
associations were observed with continuous baseline BMI and BMI categorized 
according to the WHO cut-offs. (Table 4-4) Baseline obesity was positively associated 
with the annual percent change in prostate volume (β= 0.09, 95% CI: 0.03-0.15), and this 
association was similar when assessed using baseline BMI and categorical BMI based on 
WHO cut-offs. (Table 4-4) 
Table 4-5 displays the predicted annual percent change in PSA associated with the 
intercepts of PSA, prostate volume and BMI and the slopes of prostate volume and BMI. 
Baseline BMI was inversely associated with the rate of change in PSA, with a 5 unit 
increase in baseline BMI corresponding to a 0.003% decrease in the annual percent 
change in PSA (β=-0.003, 95% CI: -0.006, -0.0003), adjusting for age, baseline PSA, 
baseline prostate volume, annual percent change in prostate volume and the rate of 
change in BMI (see Model 1 in Table 4-5).  Age, baseline PSA level and change in 
prostate volume were also positively associated with the rate of change in PSA when 
mutually adjusted for the other covariates. The estimated effects of the two BMI 
predictors and the two prostate-volume predictors did not change appreciably when the 
other two predictors were excluded from the model (see Models 2 and 3 in Table 4-5). 
Table 4-6 summarizes the means and standard deviations of the predicted 
intercepts of and rates of change in plasma volume and PSA mass, by 10-year age 
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category and baseline obesity status. The predicted baseline values of both plasma 
volume and PSA mass were strongly associated with age (both p<0.001); plasma volume 
decreased and PSA mass increased with increasing age. Men who were obese at baseline 
had a higher age-adjusted mean plasma volume level at baseline (3.69 L) when compared 
to men who were not obese (3.33 L) (p<0.001). The age-adjusted mean PSA mass at 
baseline was similar for obese and non-obese men at baseline (p = 0.79) (Table 4-6). The 
rate of change in plasma volume over time decreased with increasing age (p< 0.001). The 
annual percent change in PSA mass was associated with age, although not linearly as the 
annual percent change in PSA mass increased and then decreased with increasing age 
(p=0.05).  Baseline obesity was inversely associated with the rate of change in plasma 
volume after adjustment for age. The mean annual percent change in PSA mass differed 
little by baseline obesity status (p=0.23). (Table 4-6)
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Discussion 
 In this longitudinal study of Caucasian men ages 40-79, baseline obesity, defined 
as BMI ≥ 30 kg/m2, was inversely associated with baseline PSA level, and inversely 
associated with the annual percent change in PSA over time after adjustment for age, 
baseline PSA, and the rates of change in BMI and prostate volume. Baseline obesity was 
positively associated with the annual percent change in prostate volume after adjustment 
for age. Baseline obesity was also associated with increased plasma volume at baseline, 
and the rate of change in plasma volume over time after age adjustment. Baseline obesity 
did not influence either the baseline value or annual percent change in PSA mass over 
time after adjustment for age.  
The hypothesis that a detection bias for prostate cancer exists among obese men is 
based on the following findings: 1) Obese men have decreased cross-sectional PSA 
levels, due to either lower testosterone levels (7) or the hemodilution of PSA among 
obese men (10); and 2) BMI is associated with larger prostate volumes, impacting 
detection via digital rectal exams and biopsies (45, 46, 84). This study expands on these 
previous findings by further elucidating these detection issues. This was accomplished by 
assessing 1) whether BMI was associated with PSA cross-sectionally and longitudinally, 
2) whether this association was due in part to hemodilution, and 3) whether BMI 
influences prostate volume over time.  
Our finding that baseline BMI was inversely associated with PSA levels in cross-
sectional analysis is similar to previous studies that found lower PSA levels among obese 
men when compared to non-obese men or decreasing PSA with increasing BMI (8, 9, 
43). Furthermore, our results suggest that baseline obesity has more influence on PSA 
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change than does the rate of change in BMI. This finding may be due to the mean rate of 
change in this cohort being very small, rather than the absence of an association of the 
rate of change in BMI with PSA over time. Baseline BMI was also inversely associated 
with the rate of change in PSA adjusting for age, baseline prostate volume, baseline PSA, 
and the rates of change in BMI and prostate volume. These results suggest that in 
addition to its influence on concurrent PSA level, BMI also influences the annual percent 
change in PSA over the 15 years of follow-up. This finding is important, as the rate of 
change in PSA or PSA velocity is currently the preferred measure used to diagnose 
prostate cancer (13, 72). It is therefore possible that the resulting detection issues related 
to the influence of BMI on PSA may also limit using PSA velocity to screen obese men 
for prostate cancer. With increasing BMI, a decreasing rate of change in PSA may 
influence detection by possibly delaying diagnoses in men with higher BMI or potentially 
missing them all together because obese men may not experience enough of a change in 
PSA to be recommended for biopsy.  
Our findings also suggest that the association between BMI and PSA is at least in 
part due to the hemodilution of PSA, as baseline obesity was associated with increased 
plasma volume but not with PSA mass (the product of PSA concentration and plasma 
volume) at baseline. Similar associations were seen longitudinally as well, as baseline 
obesity was associated with the rate of change in plasma volume but not with the annual 
percent change in PSA mass over time. Our cross-sectional results are similar to previous 
studies that found plasma volume to increase with increasing BMI but no relation 
between BMI and PSA mass.(10, 85) Our study takes these findings one step further by 
suggesting that the hemodilution of PSA is in part, responsible for the association of 
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baseline BMI and changes in PSA over time. This has important implications for prostate 
cancer screening and detection as current prostate cancer screening practices that use 
cross-sectional or longitudinal measures of PSA without taking into account this 
metabolic condition may result in missed or delayed diagnoses due to obese men being 
less likely to be referred for biopsy.  
Our results further support the notion that these detection issues among obese men 
are also in part due to the influence of BMI on prostate volume. In this cohort, baseline 
BMI was positively associated with the annual percent change in prostate volume. Our 
results are similar to several previous studies that found obese men to have larger 
prostates (11, 45). Most prostate cancers detected upon biopsy are very small, resulting in 
more difficult detection upon biopsy in men with larger prostates. It is therefore likely 
that fewer cancers are then detected in obese men due to their larger prostate size or that 
diagnoses are delayed resulting in later stage disease at diagnosis. Previous studies have 
shown obese men are more likely to be diagnosed with later-stage disease and less likely 
to be diagnosed with early-stage disease (37, 38, 40), suggesting that the consequences of 
prostate volume’s role in this detection issue among obese men has important 
implications in terms of prostate-cancer aggressiveness.  
Overall, the findings from our study, taken together with findings from previous 
studies, suggest the detection bias among obese men is in part due to the influence of 
BMI on both prostate volume and the hemodilution of PSA. (11, 86) This bias, coupled 
with the findings that obese men present with later-stage disease (38) and have worse 
outcomes after treatment, including greater risk of recurrence (87, 88), suggest it may be 
reasonable to take into consideration whether a man is overweight or obese when he 
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screens with PSA or is biopsied for prostate cancer. In order to minimize this detection 
bias, it may be prudent to lower PSA cut-offs for overweight or obese men and/or take 
more cores in these men at biopsy.  
The strengths of this study include the use of longitudinal data with 15 years of 
follow-up that contained rigorously collected repeated measures of BMI, prostate 
volume, and serum PSA levels. Censoring outcome values collected after prostate cancer 
diagnosis, BPH treatment or prostate surgery yields a disease-free, asymptomatic 
population. However, this study also has potential limitations that need to be considered. 
This cohort is comprised of solely Caucasian men, limiting our inferences to other racial 
and ethnic groups. Longitudinal measures of testosterone were not available in this 
cohort; therefore, we could not assess whether testosterone levels also influence the 
detection of prostate cancer in obese men. The longitudinal nature of these data may lend 
itself to problems with attrition; however, previous work in this cohort found that 
participant dropout was not associated with chronic diseases or serum PSA levels 
adjusted for age (66), thus suggesting that bias resulting from attrition may be small. 
Finally, there may have been unmeasured time-dependent confounders that we were 
unable to account for in our analyses. 
In conclusion, baseline obesity was associated with the rate of changes in both 
PSA and prostate volume. Our results suggest that the inverse association of obesity with 
prostate–cancer diagnosis is at least partly due to detection bias, which is due to larger 
prostate volumes and PSA hemodilution in obese men.  Future research should focus on 
further elucidating what role BMI plays in the detection of prostate cancer in other 
racially heterogeneous populations. 
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Table 4-1: Participant characteristics by baseline obesity status in 545 men 
1Age at baseline 
2 p-value from chi-square test for association 
3 p-value from 2-sided Cochran-Armitage test for trend 
 
Characteristic Not Obese  
(BMI < 30 kg/m2) 
N=404 
Obese  





Age1, years    
  40-49 163(40.4) 69(48.9) 0.032 
  50-59 104(25.7) 39(27.7)  
  60-69 82(20.3) 19(13.5)  
  70+ 55(13.6) 14(9.9)  
Marital Status    
  Single, divorced, widowed, separated 41(10.1) 11(7.80) 0.41 
  Married/living together 361(89.4) 130(92.2)  
Education    
  Less than high school graduate 39(9.65) 19(13.5) 0.18 
  Finished high school/some college 184(45.5) 71(50.3)  
  College degree and beyond 178(44.1) 51(36.2)  
Salary    
  <$25,000 66(16.3) 27(19.1) 0.52 
  $25,000-$44,999 109(27.0) 33(23.4)  
  $45,000-$64,999 109(27.0) 36(25.5)  
  $65,000+ 97(24.0) 42(29.8)  
Diabetes at baseline    
  No 392(97.0) 129(91.5) 0.006 
  Yes 12(3.0) 12(8.5)  
Hypertension at baseline    
  No 310(76.7) 92(65.3) 0.008 
  Yes 94(23.3) 49(34.8)  
PSA at baseline (ng/mL)    
  Mean (SD) 1.37(1.37) 1.13(1.13) 0.06 
Prostate volume at baseline (mL)    




Table 4-2: Overall and age-stratified distributions of observed baseline and predicted rate of change for BMI, PSA and prostate volume  
 
 Overall 40-49 years 50-59 years 60-69 years 70+ years 
Observed baseline value Median 
 (Q1, Q3) 
Median 







p value*  

































Predicted rate of change       
BMI  (change/year) 0.14  
(0.07, 0.19) 
0.16 



















Prostate volume (% change/year) 2.19  
(1.67, 2.83) 
2.26 












Table 4-3: Cross-sectional associations between (a) BMI and PSA (b) BMI and prostate 
volume and (c) prostate volume and PSA from unadjusted linear regression models 
 
 (a) Log PSA (b) Log Prostate Volume  (c) Log PSA 
























































Table 4-4: Beta coefficients and 95% confidence intervals describing the association of 
baseline obesity with annual percent change in PSA and annual percent change in prostate 
volume 
 
*All models are adjusted for age and age*time and PSA and volume are log transformed 
1 Age in this model defined as age at baseline PSA blood draw and time defined as time 
since baseline blood draw 
2 Age in this model defined as age at baseline volume measurement and time defined as 







Beta  95% CI Beta 95% CI 
BMI (continuous) -0.01 -0.02, 0.004 0.01 0.004, 0.015 
Obesity 
  BMI < 30 kg/m2 












0.03, 0.15  
BMI (WHO cut-offs) 
  <25 
  25-29 
  30-34 























Table 4-5: Beta coefficients and 95% confidence intervals describing the associations of the intercepts and slopes of PSA, BMI and 










** Slopes and intercepts were obtained from models of BMI and natural log-transformed PSA and prostate volume. 
 Model 1 Model 2 Model 3 
  
PSA (% change/year)  
 
PSA (% change/year)  
 















Baseline age (per 10 years) 0.003 0.0002, 0.006 0.002 -0.0008, 0.004 0.003 0.0005, 0.006 
PSA intercept  (ng/mL) 0.017 0.012, 0.021 0.022 0.018, 0.025 0.017 0.013, 0.022 
BMI intercept (per 5 kg/m2) -0.003 -0.006, -0.0003 -0.002 -0.005, 0.0007 --  
Change in BMI (per 5 kg/m2/yr) -0.04 -0.14, 0.062 -0.023 -0.12, 0.08 --  
Prostate volume intercept (mL) -0.0004 -0.012, 0.011 --  -0.002 -0.013, 0.0092 
Change in prostate volume  
(% change/yr) 
0.67 0.40, 0.94 --  0.65 0.37, 0.92 
       
R2, F test p value 0.32 <0.0001 0.28 <0.0001 0.31 <0.0001 
Multiple correlation (R) 0.56  0.53  0.56  
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Table 4-6: Mean and standard deviations of the adjusted predicted intercepts and slopes of plasma volume and PSA mass by age category 
and baseline obesity status (N=545) 
 
Baseline Characteristic Plasma volume 
intercept 





change in PSA mass 
Overall* 3.42 (0.27) 0.004 (0.007) 1.21 (0.67) 3.56 (2.95) 
p-value <0.001 0.002 <0.001 <0.001 
Age (years)     
40-49 3.48 (0.29) 0.008 (0.006) 0.95 (0.49) 2.79 (2.89) 
50-59 3.45 (0.25) 0.005 (0.005) 1.14 (0.59) 4.23 (3.06) 
60-69 3.35 (0.24) -0.002 (0.005) 1.59 (0.69) 4.38 (2.87) 
70+ 3.28 (0.24) -0.002 (0.006) 1.71 (0.83) 3.70 (2.36) 
p-value <0.001 <0.001 <0.001 0.05 
Baseline Obesity*     
BMI <30 kg/m2 3.33 (0.22) -0.005 (0.007) 1.22 (0.69) 3.77 (2.83) 
 BMI ≥30 kg/m2 3.69 (0.23) -0.001 (0.008) 1.17 (0.62) 2.95 (3.23) 
p-value <0.001 <0.001 0.79 0.23 










Chapter 5  




 The previous chapters of this dissertation evaluated whether metabolic conditions, 
specifically diabetes, hypertension and obesity were associated with prostate cancer risk and 
detection through their influence on PSA. The results from the previous chapters suggest that 
both the incidence and detection of prostate cancer through PSA testing were influenced by 
metabolic conditions. However, in order to better understand what role these conditions play in 
influencing the detection of prostate cancer, their impact on whether prostate biopsies are 
performed and their association with the outcomes of the biopsies need to be considered. 
Therefore, the goal of this additional analysis was to determine whether baseline diabetes, 
hypertension or obesity, alone and in combination with each other influence the likelihood of 
having a prostate biopsy among the 2,445 men in OCS, as well as the result of the prostate biopsy 
among the 519 men who received biopsies during follow-up. 
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Materials and Methods 
 The parent cohort of the Olmsted County Study (N=2,445) was used to evaluate how the 
metabolic conditions influence the likelihood of having a prostate biopsy during follow-up. Men 
who underwent biopsies during follow-up were identified through detailed review of medical 
records, yielding a total of 519 biopsies. Men who reported using antihypertensive medication 
prior to baseline or who reported a physician diagnosis of hypertension at baseline were 
considered hypertensive for this analysis. Men who reported diabetes at baseline were considered 
diabetic. A trained research assistant measured height and weight, and BMI was calculated by 
dividing the weight in kilograms by the height in meters squared. Men with a BMI greater than or 
equal to 30 kg/m2 were considered obese, based on the definition established by the World Health 
Organization (WHO) (1). PSA level as measured in the serum in ng/mL and abnormal PSA levels 
at baseline were defined as PSA greater than 4 ng/mL. 
Participants’ person-time contribution began on the date they completed their baseline 
questionnaires and ended at the date of first biopsy or the last date of passive surveillance chart 
review, whichever came first. Age-adjusted hazard (incidence rate) ratios and 95% confidence 
intervals measuring the associations of the demographic and metabolic characteristics with 
prostate cancer biopsy were estimated using Cox proportional hazards regression (SAS procedure 
proc phreg). The estimated effects of the  metabolic conditions alone, as well as their interactions 
on prostate cancer biopsy risk were assessed using a single, multivariable Cox model also 
adjusting for age. To determine if baseline PSA level modified the associations between the 
metabolic conditions combinations and likelihood of biopsy, interaction (product) terms with 
PSA were included in the overall adjusted model. 
Among the 519 men who received biopsies during follow-up, the outcome of the biopsy 
was classified as either positive or negative for the presence of prostate cancer, resulting in 146 
positive biopsies. Age-adjusted odds ratios and 95% confidence intervals measuring the 
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associations of the demographic and metabolic characteristics with biopsy outcome were 
estimated using multivariable logistic regression. The effects of the various combinations of the 
metabolic conditions, as well as their interactions, on biopsy outcome was assessed using a 




Among the 2,445 men in this cohort, prostate biopsy was positively associated with age 
(HR for 1 year: 1.05; 95% CI: 1.04, 1.06) (results not shown). The incidence rate of biopsy was 
greater in men with a family history of prostate cancer than in men without a family history of 
prostate cancer (Table 5-1: HR: 1.46; 95% CI: 1.1, 1.88). Also, men who used statins prior to 
baseline were approximately 25% less likely to have a prostate biopsy during follow-up when 
compared to men who did not use statins prior to baseline (HR: 0.77; 95% CI: 0.64, 0.94) (Table 
5-1). 
 Table 5-1 also displays the age-adjusted hazard ratios for each metabolic variable, 
unadjusted for the others. Men with a history of diabetes had a slight reduced likelihood of 
prostate biopsy compared to men without diabetes at baseline after adjusting for age. (Table 5-1: 
age-adjusted HR: 0.88; 95% CI: 0.58, 1.3). Hypertensive men slightly more likely to have a 
prostate biopsy than were non-hypertensive men, (age-adjusted HR: 1.08; 95% CI: 0.89, 1.31), 
nor were obese men when compared to non-obese men at baseline after adjusting for age (age-
adjusted HR: 0.92; 95% CI: 0.74, 1.15). Adjustment for age, family history of prostate cancer and 
baseline statin use did not change these results (results not shown). 
 Despite small numbers of biopsies, the combined categories of the three conditions were 
also examined. Figure 5-1 displays the age-adjusted hazard ratios of prostate biopsy for all eight 
combinations of the three components of the metabolic syndrome. Compared to men with no 
components of the syndrome, men with all three---the metabolic syndrome—had a reduced rate 
of prostate biopsy, adjusting for age (HR: 0.60; 95% CI: 0.22, 1.60); however, this estimate is 
imprecise because there were only 4 biopsies in the group with all three conditions. The presence 
of diabetes alone was nearly unassociated with prostate cancer (HR: 1.01; 95% CI: 0.50, 2.1), but 
men who were hypertensive, or diabetic and not obese were less likely to have a prostate biopsy 
compared to men who did not have any of the three conditions (Figure 5-1) Obesity and 
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hypertension alone were associated with a slight increased risk of prostate biopsy; however, the 
combination of the two was associated with a decreased risk of prostate biopsy compared to men 
with none of the conditions (age-adjusted HR: 0.88; 95% CI: 0.60, 1.29) (Figure 5-1).  
As baseline PSA was positively associated with an increased rate of prostate biopsy, 
adjusting for age, (HR: 1.09; 95% CI: 1.05, 1.13) (results not shown), the interaction between the 
metabolic components and baseline PSA level was examined. The notable departures from 
multiplicative effects in the proportional hazards model that contained age, the metabolic 
components alone, their interactions as well as their interactions with PSA, were the interactions 
between diabetes and PSA (p = 0.04), hypertension and PSA (p = <0.01), hypertension, obesity 
and PSA (p = 0.01), and the four-way interaction between the components and PSA (<0.01). (data 
not shown).    
 Table 5-2 displays likelihood of biopsy associated with the baseline metabolic conditions 
independent of the other metabolic conditions. Among the 519 men who were biopsied in this 
cohort, men with diabetes were approximately 25 percent less likely to have a positive prostate 
biopsy compared to men without diabetes after adjustment for age (OR: 0.74; 95% CI: 0.28,1 
.93). Men with hypertension were also less likely to have a positive biopsy, but men who were 
obese at baseline were slightly more likely to have a positive biopsy during follow-up when 
compared to men without these conditions. The number of metabolic components present was 
associated with the odds of a positive biopsy, as the presence of one component was associated 
with a slightly increased odds of positive biopsy and the presence of 2 or more components was 
associated with a 33 percent reduced odds of positive biopsy after adjustment for age. 
Table 5-3 displays the age-adjusted odds ratios of prostate biopsy for the combinations of 
the three components of the metabolic syndrome, mutually adjusted for each other and age. Men 
with diabetes alone were less likely to have a positive biopsy whereas men with diabetes and 
hypertension were more likely to have a positive biopsy result. Men with hypertension alone or 
obesity alone were more likely to have a positive biopsy, but men with both of these conditions 
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were less likely to have a positive biopsy.  Men with all three components were less likely to have 
a positive biopsy when compared to men without any of these conditions (age-adjusted OR: 0.72; 




 In this cohort, the presence of metabolic conditions, specifically diabetes, hypertension 
and obesity were associated with both the rate of receiving a prostate biopsy and the probability 
that the prostate biopsy was positive. While the presence of any of the three components alone 
was associated with an increased risk of prostate biopsy, when in combination with each other 
such that multiple comorbidities were present, there was a reduced likelihood of prostate biopsy 
after adjustment for age. While men who were hypertensive and obese were less likely to have a 
positive biopsy, men who were hypertensive and diabetic were more likely to have a positive 
biopsy after adjustment for age. Furthermore, the presence of multiple metabolic components was 
also associated with a reduced likelihood of a positive biopsy after adjusting for age. 
Overall, the findings that the presence of multiple conditions together results in a 
decreased risk of prostate biopsy may be indicative of a detection bias as described in previous 
chapters of this dissertation. Furthers supporting this hypothesis are the findings that the presence 
of 2 or 3 components is associated with a decreased likelihood of biopsy, while the presence of 
one component is associated with an increased risk. It may be that because men with multiple 
conditions have lower PSA levels, they are as a result less likely to be recommended for biopsy, 
resulting in a lower rate of biopsies among these groups when compared to men with none of 
these conditions. However, men with one of the metabolic conditions alone are more likely to 
have a biopsy, which may be a reflection that men with these conditions are more closely 
followed by a physician, and as such, are more likely to have a prostate biopsy when necessary, 
inflating the number of men receiving biopsies in these groups. 
Among those who received biopsies during follow-up, men with diabetes alone, 
hypertension and obesity or all three of the metabolic conditions were also less likely to have a 
positive biopsy, suggesting that the detection of prostate cancer from biopsy tissue may be more 
difficult in the presence of these conditions. These results should be interpreted with caution as 
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only 519 men in this cohort received biopsies during follow-up, thus limiting inferences we can 
make regarding the influence of these metabolic conditions on biopsy outcomes.  Taken together 
with the findings regarding the likelihood of biopsy, these findings may suggest that the influence 
of these conditions on prostate cancer may be in part be due to their influence on biopsy detection 
specifically.  
In conclusion, the results from this additional analysis suggest that while the presence of 
the metabolic components alone is associated with a slightly increased rate of prostate biopsy, 
multiple conditions together are associated with a reduced rate of prostate biopsies as well as a 
reduced likelihood of positive biopsies. Taken together, these results suggest that these conditions 
do play at least a part in influencing prostate cancer incidence through their impact on prostate 
cancer detection. Future studies need to elucidate in larger more diverse samples how these 
conditions to influence detection and whether this is resulting in a lower incidence of prostate 
caner among these groups as a result. 
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Table 5-1: Age-adjusted Hazard Ratios (HR) and 95% Confidence Intervals (CI) of 











HR (95% CI) 
Demographics    
Age at baseline 135 1131  
  40-49 151 1140 -- 
  50-59 150 747 -- 
  60-69 83 182 -- 
  70+   -- 
Family history of prostate cancer    
  No 450 2760 1 
  Yes 69 441 1.46(1.1, 1.88) 
Education    
  Less than high school graduate 67 260 1 
  Finished high school/some college 247 1506 0.90(0.68, 1.19) 
  College degree and beyond 199 1383 1.12(0.84, 1.51) 
Marital status    
  Single, divorced, widowed, separated 52 268 1 
  Married/living together 466 2922 0.94(0.71, 1.26) 
Salary    
  <$25,000 111 531 1 
  $25,000-$44,999 160 931 1.10(0.86, 1.41) 
  $45,000-$64,999 103 722 1.02(0.77, 1.36) 
  $65,000+ 126 930 1.41(1.07, 1.85) 
Statin use prior to baseline    
  No 377 2267 1 
  Yes 142 934 0.77(0.64, 0.94) 
Metabolic Conditions     
Diabetes diagnosis at baseline    
  No  495 3122 1 
  Yes 24 78 0.88(0.58, 1.33) 
Hypertensive at baseline     
  No 364 2459 1 
  Yes 155 742 1.08(0.89, 1.31) 
Obesity    
  Not Obese (<30 kg/m2) 419 2573 1 
  Obese (≥30 kg/m2) 98 625 0.92(0.74, 1.15) 
Number of Metabolic Conditions    
  0 290 1944 1 
  1 185 1085 1.17(0.96, 1.40) 


















Table 5-2: Age-adjusted Odds Ratios (OR) and 95% CI of probability of having a positive 
biopsy among 519 men with biopsies during follow-up 
 
 








Metabolic Conditions     
Diabetes diagnosis at baseline    
  No  355 140 1 
  Yes 18 6 0.74(0.28 1.93) 
Hypertensive at baseline     
  No 261 103 1 
  Yes 112 43 0.88(0.56, 1.35) 
Obesity    
  Not Obese (<30 kg/m2) 301 118 1 
  Obese (≥30 kg/m2) 70 28 1.04(0.64, 1.69) 
Number of metabolic components    
  0 301 118 1 
  1 70 28 1.09(0.73, 1.65) 
  2 or 3 70 28 0.67(0.32, 1.45) 
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Table 5-3: Age-adjusted ORs and 95% CI of probability of having a positive biopsy among 
519 men with biopsies during follow-up 
 








Metabolic Conditions     
No metabolic components 210 80 1 
Diabetes alone 7 1 0.34(0.04, 2.85 
Hypertensive alone 79 33 1.01(0.62, 1.65) 
Obesity alone 41 22 1.49(0.83, 2.68) 
Diabetes and Hypertensive 5 4 1.69(0.44, 6.59) 
Hypertensive and Obese 24 5 0.50(0.18, 1.37) 











Chapter 6  
Conclusions 
Summary of Findings 
In summary, the findings from this dissertation suggest that metabolic 
disturbances influence both the risk and detection of prostate cancer. The findings from 
Chapter 2 highlight that type 2 diabetes, obesity and hypertension alone and in 
combination were differentially associated with prostate cancer risk. When combined 
together applying a modified definition of the metabolic syndrome, the presence of these 
three conditions at baseline slightly decreased the risk of prostate cancer over 15 years of 
follow-up. Men who were hypertensive and obese at baseline had a lower incidence rate 
of prostate cancer than did men without either condition, while men with hypertension 
alone were at increased risk of disease. The presence of diabetes alone at baseline was 
associated with decreased incidence of prostate cancer when compared to men with none 
of these metabolic conditions.  
The metabolic conditions evaluated in this dissertation also influenced the 
detection of prostate cancer, through their influence on the changes in serum PSA levels 
over time as illustrated in Chapters 3 and 4 and their influence on the likelihood and 
results of prostate biopsies. The presence of type 2 diabetes at baseline was associated 
with an attenuated increased in PSA over the 15 years of follow-up after adjustment for 
age. Specifically, men with type 2 diabetes experienced less of a change in PSA when 
compared to men without type 2 diabetes at baseline. Hypertension did not influence the 
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change in PSA levels over time in this cohort. Obesity, specifically baseline BMI, was 
inversely associated with baseline PSA levels as well as the change in PSA over time in 
this cohort. Additionally, baseline BMI was positively associated with the annual percent 
change in prostate volume. The relation between BMI and PSA is in part due to the 
hemodilution of PSA, as baseline BMI was associated with both the baseline levels and 
rate of change in plasma volume and not associated with either baseline levels or annual 
percent change in PSA mass. The presence of multiple metabolic conditions together 
decreased the likelihood of biopsy when compared to men with no conditions and also 
decreased the probability of a positive biopsy result among the men who received 
biopsies in this study.  
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Discussion of Findings 
 
Metabolic Syndrome and Prostate Cancer Risk 
In this dissertation, a slight inverse association was observed between the 
presence of all three components of metabolic syndrome and prostate cancer. While there 
was an association between the presence of one component (hypertension) and an 
increase in the rate of prostate cancer adjusting for age, an increasing number of 
components was not found to be positively and consistently associated with prostate 
cancer. The discrepancy in results may in part be due to the varying definitions of 
metabolic syndrome used in the current and previous investigations (i.e., three vs. more 
than three components of the metabolic syndrome) or to the small number of prostate 
cancer cases detected among men with all three components. Additionally, while 
definitions of metabolic syndrome recommended by the WHO and Adult Treatment 
Panel III and modified versions were used in previous investigations, this dissertation 
focused on the combination of the components rather than the syndrome alone. Finally, it 
is possible that the differing results are due to the unaccounted influence of dyslipidemia 
on prostate cancer risk in the OCS. 
A plausible etiologic hypothesis is that the metabolic syndrome reduces the risk of 
prostate cancer through the action of sex hormones. The cross-talk between androgens, 
sex hormone-binding globulin and insulin is thought to influence prostate cancer (26), 
and men with metabolic syndrome exhibit decreased testosterone levels (64), thus 
potentially decreasing their risk of prostate cancer. It is also possible that these results are 
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explained in part by a detection bias that results in a lower rate of prostate cancer among 
obese men.  
 
Diabetes and Prostate Cancer Risk 
 A weak inverse association between diabetes and prostate cancer was observed in 
this dissertation, but it may have been a chance finding as only 9 cases of prostate cancer 
among diabetics were observed. Alternatively, these findings may obscure the changing 
association between insulin level and prostate cancer risk over the course of diabetes 
progression. Insulin levels are initially high in type 2 diabetes but fall over time due to 
the damage to the pancreatic ß cells. Therefore, the relation between diabetes and prostate 
cancer may change from positive to inverse as diabetes progresses. Unfortunately, 
information on insulin levels or the duration of diabetes was not available in the OCS. 
 
Obesity and Prostate Cancer Risk 
Obesity (BMI ≥30 kg/m2) was minimally and inversely associated with prostate 
cancer in this cohort when compared to a BMI of less than 30 kg/m2, which is similar to 
findings from previous studies (35, 47, 57). In addition, obesity has been differentially 
associated with aggressive versus non-aggressive prostate cancers; a reduced risk of low-
grade disease and an increased risk of high-grade disease have been observed for obese 
men (40, 62, 63). The results from this dissertation, however, did not change when 
stratified by grade and stage of prostate cancer (data shown in Appendix 1). 
Alternatively, several studies, in addition to this dissertation, suggest that a detection bias 
associated with obesity may partly explain the inverse association between obesity and 
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prostate cancer incidence (7). While it is plausible that obesity can influence the growth 
of prostate cancer through the action of adipocytes, it is unclear if the associations seen in 
this study and in previous work are biased due to detection issues that occur among obese 
men. 
 
Hypertension and Prostate Cancer Risk 
It has been postulated that hypertension could increase the risk of prostate cancer 
through sympathetic nervous system activity that can result in androgen-mediated 
stimulation of prostate cancer growth (53). Men with both hypertension and obesity had a 
lower rate of prostate cancer in this dissertation compared to men with neither condition, 
and men with hypertension who were not obese were at increased risk. This apparent 
heterogeneity of effects may be influenced by the likelihood of these men receiving 
biopsies. Specifically, it is possible that men with both comorbidities are less likely to be 
biopsied, as a result of physician perception that these comorbidities are more life 
threatening than prostate cancer.  
 
Diabetes and Prostate Cancer Detection 
The results from this dissertation suggest that men with diabetes have slower 
increases in serum PSA levels over time, and this might account for the lower serum PSA 
levels observed among diabetics in cross-sectional studies (50, 51). The association 
between diabetes and serum PSA levels is hypothesized to vary with the duration of 
diabetes. Thus, it is plausible that as the duration of diabetes increases, the action of 
insulin decreases and testosterone increases, resulting in subsequent drops in serum PSA 
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levels. This is supported by findings that later-stage diabetes is characterized by lower 
levels of circulating insulin, which have been associated with lower prostate-cancer risk 
and serum PSA levels (49, 73). A lower risk in later-stage diabetes may be attributable to 
the androgen regulation of PSA levels. PSA cleaves insulin growth factor binding protein 
3 (IGFBP-3), a major binding protein for insulin growth factor 1 (IGF-1), which is 
involved in insulin signaling and associated with an increase in prostate-cancer risk (74, 
75).  
 
Hypertension and Prostate Cancer Detection 
 Hypertension was not associated with change in serum PSA levels over time in 
this cohort. The lack of an association between hypertension and change in serum PSA 
levels over time in our study may be in part due to the non-specificity of prescriptions for 
hypertensive medications or to hypertensive status being defined only at baseline. It is 
possible that some non-hypertensive men were prescribed medication because of 
cardiovascular disease.  It is also plausible that men with hypertension in this cohort were 
being treated during follow-up; therefore, the effect of hypertension on serum PSA level 
is attenuated, resulting in little or no association.  
 
Obesity and Prostate Cancer Detection 
The hypothesis that a detection bias for prostate cancer exists among obese men is 
based on the following findings from previous studies: 1) Obese men have decreased 
cross-sectional PSA levels, due to either lower testosterone levels (7) or hemodilution of 
PSA among obese men (10); and 2) BMI is associated with larger prostate volumes, 
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impacting detection via digital rectal exams and biopsies (45, 46, 84). This dissertation 
expands on these previous findings by further elucidating these detection issues. The 
results of this dissertation suggest baseline obesity has more influence than BMI change 
on PSA level. This finding may be due to the mean rate of change in this cohort being 
very small, rather than the absence of an association of the rate of change in BMI with 
PSA over time. Baseline BMI was also inversely associated with the rate of change in 
PSA adjusting for age, baseline PSA and prostate volume and the rate of change in 
prostate volume and BMI. These results suggest that in addition to its influence on 
concomitant PSA levels, BMI also influences the annual percent change in PSA over the 
15-years of follow-up. This finding is important, as the rate of change in PSA–PSA 
velocity—is currently the preferred measure used to diagnose prostate cancer. (13, 72) It 
is therefore possible that the resulting detection issues related to the influence of BMI on 
PSA may also limit the use of PSA velocity to screen obese men for prostate cancer.  
Findings from this dissertation also suggest that the association between BMI and 
PSA is at least in part due to the hemodilution of PSA, as baseline obesity was associated 
with increased plasma volume but was not associated with PSA mass at baseline. Similar 
associations were seen longitudinally as well, as baseline obesity was associated with the 
rate of change in plasma volume but not associated with the annual percent change in 
PSA mass over time. This has important implications for prostate cancer screening and 
detection as current prostate cancer screening practices that use cross-sectional or 
repeated measures of PSA without taking into account this metabolic condition may 
result in missed or delayed diagnoses due to obese men being less likely to be referred for 
biopsy.  
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The findings from this dissertation further support the notion that these detection 
issues among obese men are also in part due to the influence of BMI on prostate volume. 
Baseline BMI was positively associated with the annual percent change in prostate 
volume. Most prostate cancers detected upon biopsy are very small, suggesting that 
detection is more difficult for men with larger prostates. It is therefore likely that fewer 
cancers are detected in obese men due to their larger prostate size or that diagnoses are 
delayed resulting in later stage disease at diagnosis. Previous studies have shown obese 
men are more likely to be diagnosed with later-stage disease and less likely to be 
diagnosed with early-stage disease (37, 38, 40), suggesting that the consequences of 
prostate volume’s role in this detection issue among obese men has important 
implications in terms of prostate cancer aggressiveness.  
 
Metabolic Conditions and Biopsy Detection  
Overall, the findings that the presence of multiple conditions together results in a 
decreased risk of prostate biopsy may be indicative of a detection bias as described in 
previous chapters of this dissertation. Furthers supporting this hypothesis are the findings 
that the presence of 2 or 3 components is associated with a decreased likelihood of 
biopsy, while the presence of one component is associated with an increased risk. It may 
be that because men with multiple conditions have lower PSA levels, they are as a result 
less likely to be recommended for biopsy, resulting in a lower rate of biopsies among 
these groups when compared to men with none of these conditions.  
Among those who received biopsies during follow-up, men with diabetes alone, 
hypertension and obesity or all three of the metabolic conditions were also less likely to 
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have a positive biopsy, suggesting that the detection of prostate cancer from biopsy tissue 
may be more difficult in the presence of these conditions. These results should be 
interpreted with caution as only 519 men in this cohort received biopsies during follow-
up, thus limiting inferences we can make regarding the influence of these metabolic 
conditions on biopsy outcomes. Taken together with the findings regarding the likelihood 
of biopsy, these findings suggest that the influence of these conditions on prostate cancer 
may be in part be due to their influence on biopsy detection specifically.   
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Limitations of this Dissertation 
This dissertation is limited by its reliance on self-report of diabetes and 
hypertension and may be underestimating the prevalence of these conditions in the OCS. 
However, diabetes diagnosis was validated among self-reported cases in a larger cohort 
study of diabetes in Olmsted County from 1950 to 2000 (65), and most studies show a 
concordance between self reports and medical records for chronic conditions such as 
diabetes and hypertension (80, 81). Additionally, diabetes and hypertension were 
measured only at baseline, and these analyses do not account for changes in these 
conditions during follow-up, which might have influenced subsequent prostate cancer 
risk and serum PSA levels. However, it is likely that not accounting for additional 
diagnoses of diabetes over time is attenuating the difference in prostate cancer risk and 
change in serum PSA levels in this cohort. Furthermore, age at diagnosis of diabetes and 
hypertension were not queried of men, thereby limiting the ability to make inferences 
about the progression of these conditions and the resulting influence on prostate cancer 
risk and serum PSA levels. The other aspect of the metabolic syndrome, dyslipidaemia 
was not assessed in this study because cholesterol levels were not available in the OCS. 
Therefore, this dissertation cannot infer the influence of cholesterol on prostate cancer 
risk or detection. Because of the lack of information on cholesterol levels over time, a 
modified version of the WHO definition of metabolic syndrome was used. In addition, 
longitudinal information on insulin and sex-steroid hormones were not available in this 
cohort, thereby limiting what inferences I could make regarding the role these hormones 
play in influencing the associations observed in this study. 
99 
Although the long follow-up period lends itself to problems associated with 
attrition, previous work in this cohort found that participant dropout was not associated 
with diabetes, hypertension, or serum PSA levels adjusting for age, thus suggesting the 
potential impact of this source of bias on these results may be limited (66). Our findings 
regarding the influence of obesity and diabetes on prostate cancer risk may be influenced 
by the role these conditions play in influencing prostate cancer detection. It is possible 
that the reduced risk of prostate cancer associated with diabetes and obesity in this study, 
is due to their influence on the detection of prostate cancer, rather than the incidence of 
disease.  
Finally, because this is a Caucasian sample of men, generalizing these findings to 
other racial groups may not be appropriate. The incidence rate of prostate cancer as well 
as the prevalence of the components of metabolic syndrome are thought to differ by race 
(9, 67); therefore, our effect estimates in Caucasians may not be applicable to other racial 
groups with different incidences of these conditions. However, the methods used in this 
study to estimate the effects of metabolic conditions on the incidence of prostate cancer 
can be applied to other populations from diverse settings. 
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Public Health Impact and Future Directions 
The main finding of this dissertation that metabolic conditions influence both the 
risk and detection of prostate cancer have significant implications for the aging male 
population in the US.  The prevalence of these conditions is only expected to increase in 
the coming years. Elucidating how these conditions influence risk is important because 
they are modifiable and provide potential prevention targets to decrease the incidence of 
prostate cancer. Currently, the methods we  use to assess whether these conditions are 
related to prostate cancer risk are flawed. Combining these conditions into one syndrome 
and determining the corresponding risk does nothing to help further the understanding of 
how these conditions work together or separately to influence the risk of prostate cancer. 
In addition, while a quarter of the US population qualifies as having metabolic syndrome, 
according to [what definition], the remaining 75% may have some but not all of these 
conditions clustering together. Understanding how these different conditions influence 
risk helps us understand how these conditions are involved in the etiology of prostate 
cancer.  Rather than combining them into one variable (purportedly a syndrome), we 
should also treat them as separate variables and estimate their component and joint 
effects on cancer risk. It is also possible that some of these conditions are more important 
than others in terms of their influence on prostate cancer risk, which cannot be 
determined with current methods of combining the conditions into a single metabolic 
syndrome. Therefore, moving forward, future research needs to move past just 
determining if the metabolic syndrome is associated with prostate cancer risk, and focus 
on elucidating how these conditions individually and in combination influence cancer 
risk. Larger samples, however, will be needed to achieve sufficient precision and power.  
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In addition to understanding how obesity, diabetes and hypertension influence 
risk of prostate cancer, it is crucial to gain a better understanding how these conditions 
also influence the detection of prostate cancer. With prostate cancer being a largely 
survivable cancer, it is imperative to diagnose the cancer in its early stages so all 
treatment options are available. Findings that obesity and diabetes affect the change in 
PSA over time are important, as this would have significant implications for prostate 
cancer screening. With the change in PSA currently used as the screening tool for 
prostate cancer, it is even more important to understand how the presence of comorbid 
metabolic conditions influence this test. The findings from this dissertation are alarming 
in that if diabetes and obesity really do affect PSA change, this may lead to less cancers 
being detected in men with these conditions or to delayed diagnoses in these groups. 
Delayed or missed diagnoses would impact treatment options and potentially prostate 
cancer specific survival. Furthermore, it remains to be demonstrated whether or not 
decreases in serum PSA levels drive the lower risk of prostate cancer observed among 
diabetic men and obese men. Finally, if future studies confirm the findings that a prostate 
cancer detection bias exists among obese and/or diabetic men, steps need to be taken to 
revise the current screening and diagnostic guidelines for prostate cancer so they take into 
account the presence of these conditions. It may be prudent to lower the cut-off for PSA 
when screening obese and or diabetic men for prostate cancer. In addition, specifically in 
obese men, it may be also worth biopsying a greater number of cores of the prostate to 
reduce the chance that the cancer may be missed due to increased prostate size. 
Therefore, future research should focus on elucidating what role obesity and diabetes 
play in influencing prostate cancer detection and whether these detection issues are 
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responsible for the inverse associations observed between these conditions and prostate 
cancer risk.  Larger, more diverse samples are needed so that future prevention strategies 




In summary, the findings from this dissertation suggest that the different 
combinations of metabolic conditions confer different risks of prostate cancer.  Obesity 
and diabetes influence the detection of prostate cancer, through their influence on PSA 
levels. As these conditions become increasingly prevalent and continue to be modifiable, 
it is crucial to gain a better understanding of how they influence other prevalent diseases 
of aging, such as prostate cancer, so that new prevention strategies can be developed and 
existing ones can be modified. As current screening guidelines are revised for prostate 






Equations and Extra Analyses from Chapter 2 
 
Equations for Analyses from Chapter 2 
Participants’ person-time contribution began on the date they completed their 
baseline questionnaires and ended at the diagnosis of prostate cancer or the last date of 
passive surveillance chart review, whichever came first. Age-adjusted hazard (incidence 
rate) ratios and 95% confidence intervals measuring the associations between the 
metabolic characteristics and prostate cancer incidence were estimated using Cox 





where:  time = person time at risk which  began on the date they completed their baseline 
questionnaires and ended at the diagnosis of prostate cancer or the last date of 
passive surveillance chart review, whichever came first 
DM = Diabetes and is defined as self-reported physician-diagnosed diabetes at 
baseline.  
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Obese = Obesity and was calculated using the measured height and weight from 
the clinic examination, with those ≥30 kg/m2 classified as obese.  
HTN = Hypertension was defined as those with high blood pressure at baseline 
or who reported using anti-hypertensive medication prior to baseline. 
 
This same method was used for the individual components alone (no interaction 
term), obesity and DM, DM and hypertension and obesity and hypertension interactions, 





Additional Analyses from Chapter 2 
Prostate Cancer Stage and Grade Results 
The models were then stratified and compared by disease stage (Pathological stage A/B vs. Pathological Stage C/D) and 
disease grade (Gleason Score < 7 vs. Gleason ≥ 7) at diagnosis 
 
Age-adjusted Hazard Ratios and 95% Confidence Intervals of the Associations of the Metabolic Conditions with Prostate Cancer Risk, 






-Each component was modeled separately independent of the presence of absence of the other components and compared 
to men without that component (i.e. Men with diabetes vs. men without diabetes) 
   *Men with all three components were compared to men without any of the components 
 
 




(Gleason ≥ 7) 
N=56 
Localized Disease 
(path stage A/B) 
N=22 
Advanced disease 
(path stage C/D) 
N=17 
Obese 1.10(0.50, 2.43) 1.13(0.52, 2.46) 0.98(0.55, 1.73) 0.57(0.17, 1.95) 
Hypertension 1.08(0.56, 2.07) 2.37(1.20, 4.67) 2.25(1.33, 3.81) 1.42(0.48, 4.19) 
Diabetes 2.89(0.61, 13.72) n/a 2.39(0.65, 8.79) 2.37(0.93, 6.10) 
All 3* 0.46(0.11, 1.87) n/a 0.96(0.93, 9.79) n/a 
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Age-adjusted Hazard Ratios and 95% Confidence Intervals of the Associations of the Metabolic Conditions with Prostate Cancer Risk, 









Each component was modeled either alone or in combination with the other components as displayed in the Venn Diagram 
approach in Chapter 2 
 




(Gleason ≥ 7) 
Localized Disease 
(Path stage A/B) 
Advanced disease 
(Path stage C/D) 
Obese only 1.15(0.41, 3.04) 1.34(0.53, 3.35) 0.24(0.05, 1.21) n/a 
Hypertension only 1.02(0.49, 2.13) 2.53(1.22, 5.27) 1.18(0.35, 3.92) n/a 
Diabetes only n/a n/a n/a n/a 
Obese and DM n/a n/a n/a n/a 
DM and HTN 4.64(0.55, 39.11) n/a 3.87(0.34, 44.37) n/a 
HTN and Obese 0.98(0.22, 4.45) 2.46(0.52,11.78) 0.29(0.05, 1.84) n/a 




Equations and Extra Analyses from Chapter 3 
 
Equations  
Linear mixed effects regression models were used to estimate the annual percent 
change in serum PSA levels by regressing each measure on time from initial blood draw 
and adjusting for 10-year baseline age groups. Interaction terms with time were included 
to allow for different slopes across these age groups. These models also included terms 
for diagnosis of diabetes or hypertension and interaction terms to compare intercepts and 
slopes among those with and without a diagnosis. Because of the skewed distribution, 
serum PSA levels were natural log-transformed, and therefore, annual changes represent 





where:  Diabetes is defined at baseline and time is defined as time since baseline PSA blood draw 
β0 = average intercept (offset by individual random effects ) 
β2- β4 = offset for intercepts for older age decades (reference = 40 year olds) 
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β5 := average rate of change over time (offset by individual random effects ) 
β6 – β8= offsets to the slopes for the older age decades. 





where:  Hypertension is defined at baseline and time is defined as time since baseline PSA blood 
draw 
β0 = average intercept (offset by individual random effects ) 
β2- β4 = offset for intercepts for older age decades (reference = 40 year olds) 
β5 := average rate of change over time (offset by individual random effects ) 
β6 – β8= offsets to the slopes for the older age decades. 




Additional Analyses from Chapter 3 
Additional linear mixed models were run to estimate the association of baseline diabetes or hypertension with annual percent 
change in PSA, regressing each measure on time from initial blood draw and adjusting for 10-year baseline age groups. These models 
also investigated interactions between age and time, diabetes and time, age and diabetes and the three-way interaction of age, time and 
diabetes as shown in the following tables:  






Model 1 Model 2 Model 3 Model 4 Model 5 
 


































Interactions       
















Age*Time*DM -- -- -- -- -- 0.002(0.001), 
 0.166 
1DM is defined at baseline: Self-reported diagnosis of condition or medication use prior to baseline 
2Age is defined as age at baseline blood draw 




























































Interactions   --    
















Age*Time*HTN -- -- -- -- -- 0.001(0.0006), 
 0.246 
1HTN are defined at baseline: Self-reported diagnosis of condition or medication use prior to baseline 
2Age is defined as age at baseline blood draw 





Equations for Chapter 4 
 
Linear mixed-effects models were used to examine the association of baseline 
obesity with annual percent change in PSA and annual percent change in prostate 
volume. These models included age and a categorical measure for obesity (BMI<30, BMI 
≥30) as well as an interaction (product) term between obesity and time to compare the 
slope of PSA among those who were obese and not obese. (Equation 1) Additional 
models were fit to assess the association of baseline BMI (treated as continuous), baseline 
BMI based on the WHO cut-offs, and repeated measures of BMI with the annual percent 




where:  Obese is categorized into BMI < 30, BMI ≥ 30 and time is defined as time since 
baseline blood draw 
β0 = average intercept (offset by individual random effects ) 
β2- β4 = offset for intercepts for older age decades (reference = 40 year olds) 
β5 := average rate of change over time (offset by individual random effects ) 
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β6 – β8= offsets to the slopes for the older age decades. 
Β9 = coefficient to compare different slopes over time by obesity status 
-Similar models were also run for baseline BMI, obesity @ baseline, and BMI 
categorized by WHO cut-offs at baseline. 
 
 A longitudinal 2-step analytic approach was used to examine the associations of 
the individual intercepts and slopes of BMI and prostate volume with the annual percent 
change in PSA. First, the annual percent change in PSA, BMI and prostate volume were 
estimated by individually regressing each measure on time from initial blood draw and 
age (10-year categories) using linear mixed-effects regression models. Interaction 
(product) terms were included to allow for different slopes across these age groups. Fixed 
and random effects were included to reflect both the mean effect and allow for individual 
variation in the baseline intercept and change over time.  An overall annual change in 
each measure for each man was estimated by combining the average longitudinal change 
in time (fixed effects) with the individual changes (random effects). Similarly, both fixed 
and random effects allowed determination of an overall baseline intercept for each age 
decade and allowed for offsets for individual variation. (Equations 2-4) Because of their 
skewed distributions, PSA level and prostate volume were log-transformed, and 
therefore, annual changes represent percent changes per year. The change in BMI reflects 
annual absolute changes.  








where: time is defined as time since baseline measurement of either PSA, volume or 
BMI. 
β0 = average intercept (offset by individual random effects )  
β1- β3 = offset for intercepts for older age decades (reference = 40 year olds) 
β4 := average rate of change over time (offset by individual random effects ) 
β5 – β7= offsets to the slopes for the older age decades. 
 
The second step of this approach was to estimate the effects of predicted 
intercepts of PSA, BMI and prostate volume and the predicted slopes of BMI and 
prostate volume on the predicted annual percent change in PSA (all derived from the 






where:   
psaslope= estimated psa slope calculated by combining the population average  
     effects with the individual random effects from step 1 
psaint = estimated psa intercept calculated by combining the population average  
effects with the individual random effects from step 1 
bmiint= estimated bmi intercept calculated by combining the population average  
effects with the individual random effects from step1 
volint=  estimated prostate volume intercept calculated by combining the  
population average effects with the individual random effects from step 1 
bmislope= estimated bmi slope calculated by combining the population average  
     effects with the individual random effects from step 1 
volslope= estimated prostate volume slope predicted from step 1. 
 
The adjusted predicted values of the intercepts and slopes of plasma volume and 
PSA mass were also estimated using linear mixed-effects regression models that 
individually regressed each measure on time from initial blood draw and age (10-year 
categories) and included a categorical measure for obesity (BMI<30, BMI ≥30), as well 
as an interaction term to compare the intercept and slope among those who were obese 
and not obese where appropriate. (Equations 6-8) Because of the skewed distribution, 
PSA mass was log-transformed, and therefore, annual changes represent percent changes 
per year. The change in plasma volume reflects annual absolute changes. The means and 
standard deviations of the predicted slopes and intercepts of PSA mass and plasma 








where plvolume = annual absolute change in plasma volume  
-PSA and PSA mass (PSA (ng/mL) x Plasma Volume) were log transformed and  
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